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The Mdm2 ubiquitin ligase is an important 
regulator of p53 abundance and p53-
dependent apoptosis.  Mdm2 expression is 
frequently regulated by a p53-Mdm2 
autoregulatory loop whereby p53 stimulates 
Mdm2 expression and hence its own 
degradation.  Though extensively studied in 
cell lines, relatively little is known about 
Mdm2 expression in heart where oxidative 
stress (exacerbated during ischemia-
reperfusion) is an important pro-apoptotic 
stimulus.  We demonstrate that Mdm2 
transcript and protein expression is induced 
by oxidative stress (0.2 mM H2O2) in 
neonatal rat cardiac myocytes.  In other 
cells, constitutive Mdm2 expression  is 
regulated by the P1 promoter (5' to exon 1), 
with inducible expression regulated by the 
P2 promoter (in intron 1).  In myocytes, 
H2O2 increased Mdm2 expression from the 
P2 promoter which contains two p53 
response elements (REs), one AP-1 RE and 
two Ets REs.  H2O2 did not detectably 
increase expression of p53 mRNA or 
protein but did increase expression of 
several AP-1 transcription factors.  H2O2 
increased binding of AP-1 proteins (c-Jun, 
JunB, JunD, c-Fos, FosB, Fra-1) to an 
Mdm2 AP-1 oligodeoxynucleotide probe, 
and chromatin immunoprecipitation assays 
showed it increased binding of c-Jun or 
JunB to the P2 AP-1 RE.  Finally, antisense 
oligonucleotide-mediated reduction of 
H2O2-induced Mdm2 expression increased 
caspase 3 activation.  Thus, increased Mdm2 
expression is associated with transactivation 
at the P2 AP-1 RE (rather than the p53 or 
Ets REs), and Mdm2 induction potentially 
represents a cardioprotective response to 
oxidative stress. 
 
Exposure of cardiac myocytes to sufficiently-
high levels of reactive oxygen species (ROS2) 
such as H2O2 leads to their death (1-3) and this 
probably involves a continuum from apoptosis 
to necrosis, depending the severity of the 
oxidative stress (4).  In aerobic tissues such as 
the heart, the mitochondria probably represent 
a significant source of ROS and increased 
ROS production by these organelles during 
hypoxia and ischemia-reperfusion injury may 
be particularly important in myocardial injury 
(5,6).  However, at lower concentrations, ROS 
have been reported to promote either growth 
of the cardiac myocyte (7) or to induce 
‘preconditioning’ (8), either of which 
potentially increases the ability of the cardiac 
myocyte to survive cytotoxic stresses.  H2O2-
induced oxidative stress simultaneously 
stimulates a number of potentially pro-
apoptotic and cytoprotective signaling 
pathways in the whole heart or cardiac 
myocytes (9), and the final outcome (cell 
death or survival) could depend on which 
signaling pathway(s) predominates and 
endures. 
 As shown by our microarray studies, 
H2O2 can positively and negatively regulate 
global gene expression in cardiac myocytes 
(3,10).  One gene consistently upregulated by 
H2O2 in rat cardiac myocytes at toxic and non-
toxic concentrations is the orthologue of 
transformed mouse 3T3 cell double minute 2 
(Mdm2) (3,10), a protooncogene (11,12), to 
which we will refer as Rdm23.  The human 
orthologue will be abbreviated to HDM2.  The 
Mdm2 protein binds to the pro-apoptotic p53 
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tumor suppressor transcription factor to inhibit 
its transactivating activity (13).  Perhaps more 
importantly, Mdm2 is an E3-ubiquitin ligase 
which ubiquitinates p53 and other proteins 
(13), thus promoting their proteasomal 
degradation.  Indeed, the stability of p53 
protein appears to be of major importance in 
controling its abundance (13).  In addition, 
Mdm2 may autoubiquitinate to promote its 
own degradation (14,15).  
 Regulation of Mdm2 expression is 
complex and involves two alternative 
promoters.  The P1 promoter lies 5' to exon 1 
and the P2 promoter lies within intron 1 (16).  
P1 primarily regulates constitutive expression 
of Mdm2 with P2 contributing to a lesser 
extent.  Inducible expression of Mdm2 is 
regulated by P2 which contains two p53 
response elements and, through these, p53 
itself regulates stress-induced expression of 
Mdm2 as part of a negative feedback loop 
(16).  Transcripts from the P1 promoter may 
be translated more slowly than those from P2 
because of the presence of short (but differing) 
upstream open reading frames (two in each) in 
exon 1 of both HDM2 and Mdm2 transcripts 
(17,18).  However, P2 contains additional 
response elements (AP-1, Ets) that may allow 
induction of Mdm2 expression in a p53-
independent manner (19-21).  The P1- and the 
P2-regulated transcripts can each give rise to 
two identical Mdm2 proteins with translation 
from the initiation codon in exon 3 encoding 
an Mdm2 species that migrates at about 90 
kDa on SDS-PAGE.  A truncated 76 kDa 
species can also be expressed from a second 
in-frame initiation codon in exon 4 either 
following removal of exon 3 by alternative 
splicing or by internal ribosomal entry (22,23).  
Expression of p76-Mdm2 protein is more 
favored with transcription from P1 than from 
P2, without there being any change in absolute 
p90-Mdm2 protein expression (23).  p76-
Mdm2 cannot bind to p53 or inhibit its 
transactivating activity, and it may in fact 
inhibit the actions of p90-Mdm2 (22).  Here, 
we characterize the Rdm2 gene and the 
expression of Rdm2 mRNA and protein in 
response to exposure to ROS (H2O2) in 
neonatal rat cardiac myocytes.  We 
demonstrate that upregulation of Rdm2 
expression by ROS is largely independent of 
p53 but correlates instead with transcriptional 
activation at the AP-1 response element.  
Furthermore, Rdm2 is cytoprotective against 
ROS-induced apoptosis (caspase 3 cleavage) 
in cardiac myocytes.   
 
EXPERIMENTAL PROCEDURES 
 
 Materials - H2O2 was standardized 
volumetrically before use.  It was stable at 4EC 
for at least 6 months.  Antibodies against 
Rdm2 [sc-965, a mouse monoclonal antibody 
raised to residues 154-167 of HDM2 
corresponding to residues 169-173 in Rdm2 
(Supplemental Material Fig. 1) in which 
region Rdm2 and HDM2 are identical in 
primary sequence], c-Jun (sc-45X, for 
supershifting), JunB (sc-46X), JunD (sc-74X), 
phospho-Elk-1(Ser-383) (sc-7979X), Fli-1 (sc-
356X), c-Fos (sc-52X), FosB (sc-48X), Fra-1 
(sc-605X), Fra-2 (sc-171X) and ATF2 (sc-
187X) were from Santa Cruz Biotechnology 
Inc.  Antibodies against c-Jun (9162, used for 
immunoblotting) and 17 kDa caspase-3 (9661) 
were from Cell Signaling Technology.  
Sarcomeric "-actin antibodies (A2172 ) were 
from Sigma Aldrich and appropriate 
horseradish peroxidase-linked secondary 
antibodies were from DAKO. 
 Six Santa Cruz Biotechnology Inc. 
anti-p53 antibodies were tested.  These were 
2B2.71 (sc-71819, a mouse monoclonal IgG2b 
raised against residues 370-378 of human 
p53), DO-1 (sc-126, a mouse monoclonal 
IgG2a raised against residues 11-25 of human 
p53), FL-393 (sc-6243, a rabbit polyclonal 
IgG raised against full-length human p53), Pab 
240 (sc-99, a mouse monoclonal IgG1 raised 
against residues 156-214 of mammalian p53), 
Pab 246 (sc-100, a mouse monoclonal IgG1 
raised against residues 88-93 of mouse p53), 
and R-19 (sc-1313, a goat polyclonal IgG 
raised against an epitope mapping to the C-
terminus of rat p53).  With the exception of 
DO-1 which is not explicitly specified by the 
supplier as being able to recognize rat p53, all 
other antibodies are supposed to recognize rat 
p53 on immunoblotting.  As negative and 
positive controls, we used lysates from non-
transfected 293T cells (sc-117752) and from 
293T cells transfected with mouse p53 (sc-
125766), respectively, and extracts of 
daunorubicin-treated cardiac myocytes. 
 The p53 electrophoretic mobility shift 
assay (EMSA) oligodeoxynucleotide probe 
was from Santa Cruz Biotechnology Inc. (sc-
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2579).  Other probes were synthesized by 
Sigma Genosys (Sigma Aldrich).  
Phosphorothioate-protected ODNs and 
standard oligonucleotides were from MWG 
Biotech.  Lipofectin was from Invitrogen.  
SMART RACE cDNA amplification kits were 
from Clontech/BD Bioscience. 
 Primary culture of neonatal rat 
cardiac myocytes - Myocytes (yield of 3.5 
!4.5 million cells/heart) were dissociated from 
the ventricles of 1- to 3-day-old Sprague-
Dawley rat hearts by an adaptation of the 
method of Iwaki et al. (24) as previously 
described (25).  Unless stated otherwise, cells 
were plated in gelatin-coated Primaria culture 
dishes (BD Biosciences) at a density of 2 × 106 
cells/35 mm dish or 4 × 106 cells/60 mm dish 
for 18 h in 15% (v/v) fetal calf serum.  For 
most experiments, serum was withdrawn for 
the 24 h before experimentation and the cells 
were used 2 d after their isolation. 
 Extraction of RNA, cDNA synthesis 
and semiquantitative or quantitative 
polymerase chain reaction (RT-sqPCR or RT-
qPCR) -  RNA [for which quantity and purity 
was assessed from the A260 and the A260/A280 
ratio (1.8-2.0 deemed acceptable)] was 
isolated from cardiac myocytes with RNA-Bee 
(GE Healthcare) according to the 
manufacturer’s instructions, cDNA 
synthesized with random hexamers and RT-
sqPCR (see Table 1 for details of primers) 
measurements performed as described in detail 
previously (3,10).  To ensure that there was no 
amplification of genomic DNA, primers were 
designed to cross exon boundaries where 
possible (Table 1) and controls in which the 
RT step was omitted were carried out.  The 
resulting RT-sqPCR products were analysed 
by ethidium bromide-agarose gel 
electrophoresis and the bands captured under 
UV illumination.  Sizes of PCR products were 
estimated by comparison with a NX174 RF 
DNA HaeIII digest DNA ladder or a 100 bp 
DNA ladder (Invitrogen).  Densitometric 
analysis was performed using ImageMaster 1D 
Prime, version 3.0 (GE Healthcare).  Values 
were normalized to the housekeeping gene 
Gapd.  PCR cycles used (Table 1) lay within 
the exponential phase of amplification 
(confirmed by construction of amplification 
curves from PCR over a range of cycle 
numbers).  Sequences of PCR amplicons were 
determined using an ABI 3100 Genetic 
Analyser by the Advanced Biotechnology 
Centre, Imperial College London). 
 For RT-qPCR, cDNA was prepared 
from 1 mg RNA using High Capacity Reverse 
Transcription Kits (Applied Biosystems).  
Primers for qPCR were designed with Primer 
Express v3.0 
(http://www.appliedbiosystems.com) using 
deduced Rdm2 sequences (Supplemental 
Material Fig. 2, Table 1).  qPCR was 
performed using a 7500 Real-Time PCR 
System (Applied Biosystems).  A master-mix 
containing (per reaction) 12.5 :l Sybr-Green 
Jump Start Taq Readymix (Sigma-Aldrich) 
and 5 :l oligonucleotides (200 mM forward 
and reverse primers) was dispensed into 
Optical 96-well reaction-plates (Applied 
Biosystems), and cDNA template added (7.5 
:l, 1/15 dilution in water).  PCR conditions for 
all primer pairs were 50EC for 2 min, 95EC for 
10 min, followed by 40 cycles of 95EC for 15 
s and 60EC for 60 s.  Following qPCR, 
dissociation curve analysis was performed to 
check for aberrant amplification products.  An 
absolute quantification protocol was used.  
Values were normalized to Gapd expression. 
 5´-RACE - Poly(A)+ RNA was 
purified from total RNA (150 :g) using oligo 
dT-cellulose (Sigma Aldrich).  Briefly, total 
RNA (in 600 :l deionized water) was 
incubated for 5 min at 65EC followed by 
addition of 1 vol. of 2× binding buffer [20 mM 
Tris.HCl pH 7.5, 1 M NaCl, 2 mM EDTA, 
0.1% (w/v) SDS].  Oligo dT-cellulose (5 mg in 
100 :l binding buffer) was added followed by 
rotation at room temperature for 15 min.  The 
oligo dT-cellulose was washed twice with 
binding buffer (1 ml) and twice with washing 
buffer [10 mM Tris.HCl pH 7.5, 0.2 M NaCl, 
1 mM EDTA, 0.05 % (w/v) SDS].  Poly(A)+ 
RNA was recovered in 250 :l of elution buffer 
[10 mM Tris.HCl pH 7.5, 1 mM EDTA, 0.05 
% (w/v) SDS; two incubations of 5 min at 
37EC].  The purification procedure was 
repeated and poly(A)+ RNA was precipitated 
with 50 :l of 4 M NaCl and two volumes of 
ethanol followed by centrifugation (12,000 × 
g, 15 min, 4EC).  After washing with 70 % 
(v/v) ethanol and centrifugation, poly(A)+ 
RNA was dissolved in deionized water (8 :l).  
Poly(A)+ RNA was reverse-transcribed using a 
SMART RACE cDNA Amplification Kit 
(Clontech/BD Bioscience).  Poly(A)+ RNA 
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(0.9 :g) was mixed with oligo-dT primer (10 
mM 5´-CDS primer A, 1 :l), 10 mM SMART 
II A oligonucleotide (10 mM, 1 :l) in a total 
volume of 5 :l.  This was heated at 72EC for 2 
min and cooled on ice.  Subsequently, 5× 
reaction buffer (2 :l; 250 mM Tris.HCl pH 
8.3, 30 mM MgCl2, 375 mM KCl), 10 mM 
dNTP (1 :l), 20 mM DTT (1 :l) and 1 :l 
PowerScript™ reverse trancriptase (1 :l) were 
added and mixture was incubated at 42EC for 
90 min.  Reverse transcriptase was inactivated 
at 72EC for 7 min.  The 5´-RACE cDNA 
reaction mixture (10 :l) was diluted to 250 :l 
with 10 mM Tricine pH 8.5, 1 mM EDTA and 
stored at -80EC.  Sequence corresponding to 
5´-end of Rdm2 mRNA was amplified using 
the SMART RACE cDNA Amplification Kit 
UPM (complementary for the extended 5´-end 
of the 5´-RACE cDNA) and a reverse primer 
to mRNA in exon 3 of Rdm2 exon 3 (bases 
269-302, Table 1).  For each PCR reaction, 5´-
RACE cDNA (2.5 :l) was combined with 10× 
'Advantage' Polymerase Buffer [10 :l; 40 mM 
Tricine-KOH pH 9.2, 15 mM KOAc, 3.5 mM 
Mg(OAc)2], 5'-RACE 1 primer (1 :l, 10 :M), 
10× UPM (5 :l), dNTP (10 mM) and 
Advantage 2 Polymerase Mix (1 :l).  The 
PCR programme was as follows: 94EC, 5 min; 
5 cycles of 94EC, 30 s and 72EC, 2 min; 5 
cycles of 94EC, 30 s, 70EC, 30 s and 72EC, 2 
min; then 25 cycles of 94EC, 30 s, 68EC, 30 s 
and 72EC, 2 min, and finally 72EC, 4 min.  
PCR products were analysed on ethidium 
bromide-stained 2 % agarose gels and the 
bands were captured under UV illumination.  
Products were excised from the gel and then 
purified using QIAquick PCR purification 
columns for automated sequencing (Advanced 
Biotechnology Centre, Imperial College 
London). 
 Soluble and nuclear protein extraction 
- For immunoblotting, myocytes were washed 
in ice-cold PBS (3×) and scraped into 100 :l 
(35 mm dishes), or (in the case of 60 mm 
dishes) into 80 :l (antisense experiments) or 
150 :l (remaining experiments) of ice-cold 
Buffer A [20 mM $-glycerophosphate pH 7.5, 
20 mM NaF, 2 mM EDTA, 0.2 mM Na3VO4, 
10 mM benzamidine, 5 mM DTT, 1 mM 
PMSF, 0.2 mM leupeptin, 2 :M microcystin 
LR, 10 :M E64, 1% (v/v) Triton X-100].  
After centrifugation (10,000 × g, 5 min, 4EC), 
supernatant protein concentrations were 
determined using the Bradford method (26), 
boiled with 0.33 vol SDS electrophoresis 
buffer [300 mM Tris-HCl pH 6.8, 10% (w/v) 
SDS, 13% (w/v) glycerol, 130 mM DTT, 0.2% 
(w/v) bromophenol blue] and stored at !20EC. 
 For crude nuclear extracts, PBS-
washed myocytes were scraped into 150 :l 
ice-cold Buffer B (10 mM HEPES pH 7.9, 10 
mM KCl, 1.5 mM MgCl2, 0.3 mM Na3VO4, 
0.2 mM leupeptin, 10 :M E64, 5 mM DTT, 
0.3 mM PMSF, 2 :M microcystin LR).  
Extracts were centrifuged (10,000 g, 5 min, 
4EC) and the pellets resuspended in 100 :l 
Buffer B containing 0.1% (v/v) Nonidet P40 
(NP-40).  Samples were centrifuged (10,000 g, 
5 min, 4EC) and the pellets resuspended in 50 
:l ice-cold Buffer C (20 mM HEPES pH 7.9, 
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 25% (v/v) glycerol, 0.3 mM Na3VO4, 
0.2 mM leupeptin, 10 :M E64, 5 mM DTT, 
0.3 mM PMSF, 2 :M microcystin LR).  
Suspensions were incubated on ice (1 h) with 
mixing every 15 min, and then centrifuged 
(10,000 g, 5 min, 4EC).  Supernatants were 
retained and stored at !80EC or were boiled 
with SDS electrophoresis buffer. 
 Immunoblotting - Proteins were 
separated by SDS-PAGE using between 8 to 
12% (w/v) resolving gels as appropriate with 4 
to 6% (w/v) stacking gels, and transferred to 
nitrocellulose membranes as described 
previously (27).  Gels were standardized using 
‘rainbow’ markers (GE Healthcare).  
Nonspecific binding sites were blocked (60 
min, room temperature) with 5% (w/v) non-fat 
milk powder in TBST [20 mM Tris-HCl, pH 
7.5, 137 mM NaCl, 0.1% (v/v) Tween 20].  
Blots were incubated overnight with primary 
antibodies diluted in TBST containing 5% 
(w/v) bovine serum albumin.  Membranes 
were washed in TBST (3 × 5 min, room 
temperature) and incubated (1 h, room 
temperature) with horseradish peroxidase-
conjugated secondary antibodies in TBST 
containing 1% (w/v) non-fat milk powder.  
After washing in TBST (3 × 5 min, room 
temperature), bands were detected by the 
enhanced chemiluminescence method 
(reagents from Santa Cruz Biotechnology 
Inc.).  In some cases the sensitivity of 
detection was increased by using unconjugated 
secondary antibodies  in TBST/1% (w/v) non-
 5
fat milk powder and, after washing with 
TSBT, blots were incubated with horseradish 
peroxidase-conjugated tertiary antibodies 
before detection by enhanced 
chemiluminescence. 
 Antisense ODN transfection - The 20-
mer antisense phosphothioate-protected ODN, 
5'-TGACATCTGCTCTCACTCGG-3', was 
directed against Rdm2 mRNA exon 7 bases 
602-621 (Supplemental Material Fig. 2).  A 
mixed back-bone HDM2 antisense ODN (5´-
UGACACCTGTTCTCACUCAC-3´ ) against 
the corresponding region (HDM2 mRNA 
bases 660-679, accession no. NM_002392.2) 
has been used previously to inhibit HDM2 
expression in colon cancer cells (28).  A 
random sequence (5´-
TGGATCCGACATGTCAGA-3´) was used as 
a control.  For transfection experiments, cells 
in 60 mm dishes were washed 3 times with 
antibiotic-free DMEM before exposure to 
DMEM containing 200 nM ODN and 20 
:g/ml lipofectin (Invitrogen).  Myocytes were 
incubated for 24 h at 37°C, then the medium 
was then replaced with lipofectin-free 
maintenance medium containing 200 nM 
ODN.  Cells were pre-incubated for 1 h before 
exposure to 0.2 mM H2O2 for 6 h and 
extracted into 80 :l Buffer A (see above). 
 Electrophoretic mobility shift assays 
(EMSAs) - Double-stranded ODN EMSA 
probes (see Table 2) were prepared essentially 
as described previously (29).  Briefly, ODNs 
were 5'-labelled with 15 :Ci [(32P]ATP (GE 
Healthcare) ,10 IU T4 polynucleotide kinase 
(Promega), and 1.2 :l of Promega 10 × kinase 
buffer.  The reaction mixture was incubated 
(37EC, 30 min) and the reaction then 
terminated by addition of 1 :l EDTA (13 :M).  
Excess [(32P]ATP was removed by 
centrifugation (700 g, 3 min, room 
temperature) through Chroma Spin columns 
(pore size 10) (Clontech/BD Biosciences) in 
1× TE buffer (10 mM Tris-HCl pH 8.0, 1 mM 
EDTA) and the EMSA probes were diluted to 
0.4 ng/:l.  Crude nuclear extracts (10 :g) were 
incubated (10 min, room temperature) with 4 
:l binding buffer [50 mM Tris-HCl pH 7.5, 
250 mM NaCl, 5 mM EDTA, 1 mM DTT, 
25% (v/v) glycerol] and 1 :g poly dI-dC (GE 
Healthcare), in a total volume of 20 :l.  
Radiolabelled EMSA probe (1 :l, 0.4 ng) was 
added and the mixture incubated (20 min, 
room temperature).  Samples were subjected to 
electrophoresis (120 V, 3 h) on 5% (w/v) non-
denaturing polyacrylamide gels formed in 1× 
TBE buffer (89 mM Tris, 89 mM boric acid, 2 
mM EDTA, pH 8.3) with 0.5× TBE as running 
buffer.  Gels were dried onto Whatman 3MM 
paper and exposed to X-ray film for 24 ! 48 h 
at !80EC.  Images were analysed semi-
quantitatively by densitometry (ImageMaster 
1D Prime, version 3.0, GE Healthcare).  For 
competition experiments, crude nuclear 
extracts were incubated (10 min) with the 
required amount of unlabelled competing 
probe in binding buffer with poly dI-dC as in 
the standard assay, followed by addition of the 
radiolabeled wild type probe and continuation 
of the assay in the standard manner.  For 
supershift assays, crude nuclear extracts (3 :g 
protein) were pre-incubated (1 h, 4EC) with 
1!2 :g of antibody. 
 ChIP assays - Myocytes were exposed 
to H2O2 (0.2 mM, 2 h) and formaldehyde [final 
concn. 1% (w/v)] was added to medium (10 
min, room temperature).  Cross-linking was 
terminated with 0.125 M glycine (5 min).  
Myocytes were rinsed twice in ice-cold PBS 
and scraped into 200 :l PBS containing 0.2 
mM leupeptin, 10 :M E64, 5 mM DTT, 1 mM 
PMSF and 2 :M microcystin LR.  
Suspensions were centrifuged (4,000 g, 10 
min, 4EC ) and pellets resuspended in 0.8 ml 
ChIP lysis buffer [50 mM Tris-HCl pH 8.0, 85 
mM KCl, 0.2 mM leupeptin, 10 :M E64, 5 
mM DTT, 0.3 mM PMSF, 2 :M microcystin 
LR, 0.5% (v/v) NP-40].  Suspensions were 
incubated on ice (10 min), centrifuged (4,000 
g, 10 min, 4EC ) and the pellets resuspended in 
0.8 ml sonication buffer [50 mM Tris-HCl pH 
8.0, 10 mM EDTA, 1% (v/v) SDS, 0.2 mM 
leupeptin, 10 :M E64, 5 mM DTT, 1 mM 
PMSF and 2 :M microcystin LR].  Samples 
were sonicated [5 × 30 sec, 0EC, amplitude 
30% (Sonics Vibra-Cell™ sonicator with a 2 
mm probe) followed after each sonication by 2 
min recovery in ice-water] to shear DNA into 
fragments of 200-800 bp.  Sonicated samples 
were centrifuged (4,000 g, 10 min, 4EC ) and 
the supernatants were retained.  Samples (20 
:l) for total DNA input were taken at this 
stage.  Sonicated extracts (750 :l) were diluted 
with 3.65 ml ChIP buffer [20 mM Tris.HCl pH 
8.0, 150 mM NaCl, 2 mM EDTA, 0.01% (w/v) 
SDS, 1% (v/v) Triton X100] and were pre-
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cleared with 30 :l 50% Protein A-Sepharose 
slurry containing 5 :g/ml sonicated salmon 
sperm DNA (rotation at 4EC for 30 min).  
Following centrifugation (200 g, 1 min, 4EC), 
anti-transcription factor antibodies (5 :g) were 
added followed by incubation (4EC, 16 h, with 
mixing by rotation).  Antibody-protein-DNA 
complexes were recovered by incubation (1 h, 
4EC, with mixing by rotation) with 50% 
Protein A-Sepharose slurry (80 :l containing 5 
:g/ml sonicated salmon sperm DNA).  Protein 
A-Sepharose-antibody-transcription factor 
complexes were recovered by centrifugation 
(200 g, 1 min, 4EC) and pellets were washed 
in low salt buffer [20 mM Tris.HCl pH 8.0, 
150 mM NaCl, 2 mM EDTA, 0.1% (w/v) 
SDS, 1% (v/v) Triton X100, 1 ml], high salt 
buffer [20 mM Tris.HCl pH 8.0, 500 mM 
NaCl, 2 mM EDTA, 0.1% (w/v) SDS, 1% 
(v/v) Triton X100, 1 ml], LiCl buffer [10 mM 
Tris.HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 
1% (w/v) deoxycholic acid, 1% (v/v) NP-40] 
and then twice in 10 mM Tris.HCl pH 8.0, 1 
mM EDTA.  Protein-DNA complexes were 
recovered by incubation (15 min, 65EC) with 
0.1 M NaHCO3, 1% (w/v) SDS (250 :l), 
samples were centrifuged (200 g, 1 min, 4EC) 
and supernatants retained.  This elution step 
was repeated and supernatants combined.  
Cross-linking was reversed by incubation (16 
h, 65EC) with 0.2 M NaCl.  DNA was 
extracted by mixing equal volumes of samples 
with phenol:chloroform:isoamyl alcohol 
(25:24:1, pH 8.0) and with separation of the 
phases by centrifugation (15,000 g, 10 min, 
4EC ).  The upper aqueous phases were 
retained and DNA was precipitated by adding 
1 vol. isopropanol for 1 h on ice.  Following 
recovery of DNA by centrifugation (21,000 g, 
10 min, 4EC), DNA was washed [70% (v/v) 
ethanol] and resuspended in 20 :l Milli-Q 
water for subsequent PCR.  PCR reactions 
were performed in 1× Buffer IV® (AB Gene, 
25 :l) containing Taq polymerase (1 U), 
dATP, dCTP, dGTP and dTTP (0.2 mM each) 
and 50 pmol primers.  PCR settings were: 
94EC, 4min; 35 × (94EC, 30s; 59EC, 30s; 
72EC, 30s), followed by 72EC, 4 min.  The 
resulting RT-PCR products were analysed by 
ethidium bromide-agarose gel electrophoresis 
and the bands captured under UV illumination. 
 Statistical analysis - Results are 
expressed as means ± SEM.  Statistical 
significance was determined by either 
Student´s t-test or one-way analysis of 
variance (ANOVA) followed by Tukey´s 
multiple comparison test, as appropriate.  P 
values of <0.05 were considered significant. 
 
RESULTS 
 
 Structure of the Rdm2 gene - Mdm2 
(NP_034916.1, 489 residues) and HDM2 
(NP_002383.2, 497 residues) are encoded by 
established genes and are highly conserved, 
sharing precise identity in about 80% of 
residues (Supplemental Material Fig. 1).  In 
contrast, Rdm2 is a predicted gene on 
chromosome 7(q22) in the NCBI database 
(http://www.ncbi.nlm.nih.gov) whose 
provisional processed transcript 
NM_001108099.1 (21 December 2008) 
encodes a protein that differs significantly 
from Mdm2 and HDM2.  A BLAST search of 
the mouse Mdm2 transcript NM_010786.3 
against the rat genome identified a 24233 bp 
sequence on the minus strand of contig 
NW_047774 corresponding to a 2930 
nucleotide transcript from 12 exons with high 
homology to the Mdm2 transcript 
(Supplemental Material Fig. 2).  The deduced 
2930 nucleotide sequence of the full-length 
transcript is identical to 2855 nucleotide 
NM_001108099.1 except that it contains an 
extra exon, the 75 nucleotide (protein-coding) 
exon 4.  A BLAST search of this exon 
revealed 14 rat ESTs with a region of precise 
sequence identity within them, thus 
establishing that exon 4 is transcribed and is 
present in mature Rdm2 mRNA.  The 
structural relationship of the first four exons in 
Rdm2 is shown in Fig. 1.  The initiation codon 
for p90-Rdm2 lies in exon 3 whereas that for 
p76-Rdm2 lies in-frame in exon 4 (Fig. 1).  
Two short and overlapping upstream open 
reading frames are present in exon 1 of the 
deduced Rdm2 mRNA sequence 
(Supplemental Material Fig. 2).  The HDM2 
and Mdm2 transcripts also each contain two 
(differing) upstream open reading frames 
(17,18).  The deduced amino acid sequence of 
Rdm2 and the Mdm2 sequence are 
approximately 90% identical, though Mdm2 
possesses a more extended Ser-rich region at 
residues 203-211 (Supplemental Material Fig. 
1). 
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 Expression of Rdm2 mRNA and 
protein in response to H2O2 - We examined 
the effects of H2O2 on Rdm2 expression by 
RT-sqPCR and RT-qPCR.  Up-regulation of 
Rdm2 mRNA was rapid being detectable at 1 h 
(Fig. 2, A-C), maximal at 2 h and maintained 
for at least 6 - 24 h.  The absolute extent of 
maximal upregulation depended on the 
technique used with sqPCR giving 3- to 4-fold 
(Fig. 2A) but with qPCR giving 20- to 30-fold 
(Fig. 2, B and C).  This probably reflects 
differences in primer design and the semi-
quantitative nature of densitometric analysis.  
At 1 h, Rdm2 mRNA was detectably-induced 
with 0.1 mM H2O2 and maximally-induced 
with 0.2-0.3 mM H2O2 (Fig. 2, D and E).  At 
higher concentrations of H2O2, Rdm2 mRNA 
abundances remained at control values (Fig. 2, 
D and E).  At 2 h of exposure, the maximal 
response was greater and was shifted to higher 
H2O2 concentrations (Fig. 2E).  These ‘bell-
shaped’ concentration dependencies are 
typical of a number of responses of the cardiac 
myocyte to H2O2.  The stimulation of Rdm2 
expression by H2O2 at 1 h was prevented by 
CHX (Fig. 3, A and B), indicating that Rdm2 is 
not an immediate early gene (i.e. the 
stimulation of its transcription by H2O2 is 
dependent on preceding de novo protein 
synthesis). 
 Since H2O2 can inhibit overall protein 
synthesis in cardiac myocytes (3), we 
investigated whether the increased abundance 
of Rdm2 transcripts was reflected in their 
translation into protein (Fig. 2, F and G).  
Rdm2 migrated at about 90 kDa on SDS-
PAGE and protein abundance increased about 
5-fold over 45 min -1.5 h (Fig. 2F).  In some 
blots, multiple bands were observed (Fig. 2, F 
and G).  Whilst one of these may represent 
p76-Rdm2, they may be degradation products 
or cross-reacting species.  Abundance of 
Rdm2 protein was maximal at 1 to 2 h and 
declined gradually thereafter (Fig. 2G), but 
remained elevated over control values (about 
2- to 3-fold greater) for up to 8 h. 
 Abundance of any individual mRNA 
species is regulated by the rate of its 
transcription and the rate of its degradation.  
The 3' untranslated region of Rdm2 mRNA 
contains an AU-rich instability element 
[probably a class I ARE consisting of 
overlapping or adjacent AUUUA pentamers 
(30), bases 2072-2085, Supplemental Material 
Fig. 2] which is orthologous with a putative 
Mdm2 mRNA ARE [see the Organism ARED 
(30) at http://brp.kfshrc.edu.sa/ARED/ and 
Reference (23)], though the Mdm2 ARE may 
be non-functional (23).  We therefore 
examined the half-life of Rdm2 transcripts 
when transcription was inhibited (by 
actinomycin D) in the absence or presence of 
0.2 mM H2O2 (Fig. 3C).  The data sets (n = 4 
for each condition) were treated as 
monophasic exponential decays.  Rdm2 
mRNA was degraded with a half-life of 1.16 h 
(k = 0.596 ± 0.140 h!1) in the absence of H2O2, 
whereas it was 1.82 h (k = 0.381 ± 0.141 h!1) 
in the presence of H2O2.  There was thus no 
significant difference in the stability of the 
transcripts under the two conditions and thus 
upregulation of Rdm2 expression results 
primarily from increased transcription. 
 Alternative promoter usage in Rdm2 
transcription - Transcription of Mdm2 and 
HDM2 is regulated by two alternative 
promoters, P1 or P2, lying 5' to exon 1 or exon 
2, respectively (16).  To assess alternative 
promoter usage for Rdm2, we used forward 
primers in exon 1 (F1) or in exon 2 (F2) and a 
reverse primer in exon 4 (Fig. 1, Supplemental 
Material Fig. 2) to produce amplicons of 333 
bp from P1 (long mRNA) or 220 bp from 
either P1- or P2 (long + short mRNAs).  In 
unstimulated cardiac myocytes, mRNA was 
detectable at 333 bp (Fig. 4A) using primer F1 
and this would contribute to the 220 bp band 
seen with primer F2 to an unassessable extent.  
Following exposure to H2O2 (0.2 mM, 2 h), 
there were no changes in the amplicon 
abundances using primer F1, but primer F2 
amplicon abundances increased about 4- to 5-
fold.  The sequences of the 220 and 333 bp 
PCR products were confirmed, indicating that  
H2O2-inducible transcription was regulated by 
the P2 promoter. 
 To confirm increased P2 promoter 
usage, we conducted 5'-RACE.  The 
theoretical lengths of the amplicons were 332 
bp for a transcript expressed from the P1 
promoter and 162 bp for a transcript expressed 
from the P2 promoter (Fig. 1, Supplemental 
Material Fig. 2).  Under control conditions, the 
major product (amplicon A) was 300 !400 bp 
in length with a weaker band (amplicon B) at 
100 !200 bp (Fig. 4B).  Following exposure to 
H2O2 (0.2 mM, 2 h), the product corresponded 
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essentially completely to the shorter amplicon 
B.  DNA sequencing confirmed that amplicon 
A corresponded to exons 1, 2 and 3 (up to the 
reverse primer site) whereas amplicon B 
corresponded to exons 2 and 3.  These results 
confirm that transcripts originate from P1 with 
some expression from P2 in the control, 
whereas promoter usage shifts primarily to P2 
following exposure to H2O2. 
 Transcription factor-response 
elements in intron 1 of the Rdm2 gene - We 
identified potential regulatory elements in 
Rdm2 intron 1by analogy with published data 
for intron 1 of the Mdm2 and HDM2 genes and 
by using TFSEARCH 
(www.cbrc.jp/research/db/TFSEARCH.html).  
A region in intron 1 of the Mdm2 (402-523), 
Rdm2 (374-494, Fig. 1) and HDM2 (406-524) 
genes is highly conserved with ~75% identity 
(Supplemental Material Fig. 3).  This contains 
the two p53-response elements (31,32) and a 
composite AP-1-Ets element [Ets(AP-1)] (33,34).  
An upstream Ets [Ets(upstream)] element in Rdm2 
and Mdm2 lies outside the conserved region 
(Supplemental Material Fig. 3, Fig. 1).  High-
stringency searching also reveals an NF-E2-
like site (35) in Rdm2 which overlaps with the 
AP-1 site and which is conserved between 
Mdm2 and HDM2.  Rdm2 and Mdm2 also 
contain a sequence reminiscent of an MZF-1 
element (36) that is not conserved in HDM2, 
though HDM2 contains an alternative MZF-1 
site (Supplemental Material Fig. 3).  However, 
neither NF-E2 or MZF-1 are thought to be 
significantly expressed outside hematopoietic 
cells (35,37), and they were not studied 
further. 
 p53 - Induction of p53 is frequently a 
response to mutational or cytotoxic 
interventions and is of established importance 
in the regulation of inducible expression of 
Mdm2 (16).  We examined whether p53 
mRNA expression increased in response to 
H2O2.  Though an amplicon of the appropriate 
size for p53 was detectable by RT-sqPCR, 
exposure of myocytes to 0.2 mM H2O2 for up 
to 24 h did not alter its expression (results not 
shown).   
 The matter of whether p53 protein in 
induced by ROS is contentious and doubts 
have been raised about the reliability of 
antibodies obtained from Santa Cruz 
Biotechnology Inc. (see Discussion).  We 
characterized six different antibodies using 
lysates of 293T cells with (positive control) or 
without (negative control) transfection with 
mouse p53 (Fig. 2).  Three of these reliably 
detected p53 by immunoblotting in our hands 
[FL-393 (Fig. 5A), Pab 240 (Fig. 5B) and 
2B2.71 (Fig. 5C)].  In all cases, p53 migrated 
slightly more rapidly than a 52 kDa marker 
(GE Healthcare, RPN800E).  With FL-393 
(Fig. 5A) and 2B2.71 (Fig. 5C), cross-reacting 
proteins were detectable in whole cell extracts 
of 293T cells, one of which migrated slightly 
more slowly than p53 at ~52 kDa.  We 
confirmed that p53 in crude nuclear extracts of 
rat cardiac myocytes which had been exposed 
to the anthracycline, daunorubicin, 
[anthracyclines induce p53 in these cells (38)] 
co-migrated with murine p53 in the positive-
control 293T cells (Fig. 5D). 
 Following exposure of cardiac 
myocytes to 0.2 mM H2O2, Rdm2 transcript 
abundances reach their maximum levels in 
crude nuclear extracts after about 2 h (Fig. 2, 
A-C).  If de novo induction of transcription 
factor proteins is a prerequisite for this event, 
it should occur over within this period.  We 
assessed whether p53 protein was induced 
over  a period of up to 8 h in crude nuclear 
extracts of cardiac myocytes exposed to 0.2 
mM H2O2  using antibodies FL-393 (Fig. 6A), 
2B2.71 (Fig. 6, B and C) and Pab 240 (Fig. 
6D).  We also assessed whether increasing the 
H2O2 concentration to 0.5 mM had any 
additional effect (Fig. 6C).  In all cases, a 
positive control for p53 protein induction was 
included using crude nuclear extracts of 
cardiac myocytes exposed to 0.5 :M 
daunorubicin for 6.5 - 7.5 h.  In no instance 
could we detect induction of p53 by H2O2 
(Fig. 6, A-D) although p53 protein was reliably 
detected following treatment with 
daunorubicin (0.5 :M for 6.5-7.5h). 
 To confirm the immunoblotting results 
(Fig. 6, A-D), we assessed whether any p53 
DNA binding activity could be detected in 
crude nuclear extracts of myocytes exposed to 
H2O2 using EMSAs.  Although daunorubicin 
increased protein binding to a p53 consensus 
response element consensus sequence, 0.2 mM 
H2O2 did not induce any detectable binding 
(Fig. 6E).  DO-1 antibodies to p53 produced a 
supershifted band on EMSAs with 
daunorubicin whereas FL-393 antibodies 
prevented binding to the probe (Fig. 6F), thus 
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confirming that the band detected on EMSAs 
with daunorubicin was indeed p53.  An 
irrelevant antibody (to JunD) did not 
supershift the complex (Fig. 6F).  Thus, using 
two independent methodologies and a variety 
of antibodies, we were unable to find evidence 
for p53 induction by H2O2.  We conclude that 
it is unlikely that p53 is responsible for the 
increased Rdm2 P2 promoter activity induced 
by H2O2. 
 Ets - We examined whether Ets 
proteins may regulate Rdm2 expression.  An 
EMSA probe corresponding exactly to the 
Ets(upstream) region (Table 2, Fig. 1) detected 
three complexes (1, 2 and 3) in crude nuclear 
extracts of myocytes exposed to 0.2 mM H2O2 
for zero or 30 min, with complex 2 showing 
evidence of inducibility (Fig. 7A).  Unlabelled 
wild type probe competed effectively for 
binding to complexes 1 and 2 (but not to 
complex 3) even at an equimolar 
concentration, whereas an unlabelled probe 
with two mutated bases did not completely 
compete for binding even when in an 100-fold 
excess (Fig. 7A).  Thus complex 3 represents 
non-specific binding.  Binding of complex 1 
was ‘constitutive’ and remained constant over 
2 h (Fig. 7B).  Nevertheless, complex 1 may 
still be important in regulation of the P2 
promoter as its transactivating activity (as 
opposed to DNA binding activity) could be 
subject to regulation [e.g. phosphorylation 
(39)].  Complex 2 was transiently induced to a 
maximum of about 8-fold after 30 min (Fig. 
7B).  By 1 h, approximately 60% of the 
induction had been lost and abundances had 
returned to baseline by 2 h (Fig. 7B), i.e. its 
peak induction significantly preceded Rdm2 
induction.  We also examined the Ets(AP-1) 
element using EMSAs with a probe 
corresponding exactly to the Ets(AP-1) region 
(Table 2, Fig. 1).  Although a complex was 
detectable, its abundance was not altered by 
exposure of myocytes to 0.2 mM H2O2 for up 
to 8 h (results not shown).  Furthermore, 
unlabeled probe for the Ets(AP-1) region did not 
effectively compete until present at a 50- to 
100-fold excess (results not shown).  Overall, 
therefore, any binding of proteins to the Ets 
sequence EMSA probes is either not inducible, 
not specific, or does not follow a time course 
appropriate for induction of Rdm2 expression. 
 AP-1- The AP-1 element is situated 
immediately 5' to the Ets(AP-1) element in the 
Rdm2 P2 promoter (Fig. 1).  An EMSA probe 
corresponding exactly to this AP-1 sequence 
(Table 2, Fig. 1) detected a complex in crude 
nuclear extracts of myocytes that was 
competed by unlabeled wild type, but not 
mutant, probe (Fig. 7C).  Levels of this 
complex were increased by H2O2 to a 
maximum at 1!2 h (Fig. 7D).  Supershift 
EMSAs were used to identify the AP-1 
proteins (the Jun and Fos family members) 
binding to the AP-1 probe.  In the absence of 
stimulation, the complex was partially 
supershifted by antibodies to JunB or JunD, 
but not by antibodies to c-Jun (Fig. 8A).  
Following exposure to H2O2  (0.2 mM 1.5 h), 
antibodies to JunB, JunD, and, additionally, c-
Jun partially supershifted the complex (Fig. 
8B).  Antibodies to c-Fos, FosB, and Fra-1 
also supershifted this complex but antibodies 
to Fra-2 or ATF2 were ineffective (Fig. 8C).  
When a mixture of all supershifting antibodies 
(c-Jun, JunB, JunD, c-Fos, FosB and Fra-1) 
was used, supershifting of the complex was 
essentially complete (Fig. 8D).  For c-Jun and 
JunB, ChIP assays confirmed that binding to 
an Rdm2 P2 sequence containing the AP-1 site 
(Fig. 1, Table 1) increased following exposure 
of cardiac myocytes to H2O2 (0.2 mM, 1.5 h) 
(Fig. 8E).  These results indicate that Fos 
and/or Jun family transcription factors bind to 
the Rdm2 P2 AP-1 sequence and this is 
increased by H2O2. 
 Expression of Jun and Fos family 
members -  We examined the time courses of 
expression of c-Jun, JunB and JunD 
transcripts and proteins in response to 0.2 mM 
H2O2.  Transcripts for both c-Jun (Fig. 9A) and 
JunB (Fig. 9B) were increased maximally 
(about 8- and 4-fold for c-Jun and JunB, 
respectively) by H2O2 after about 1 h, but had 
declined to control values by 4 h.  Protein 
abundances followed time courses essentially 
similar to those for transcripts with c-Jun 
showing a 7- to 8-fold increase (Fig. 9, C and 
D), and JunB showing a 2.0- to 2.5-fold 
increase (Fig. 9, E and F).  There were no 
changes detectable in JunD transcript or 
protein abundances (results not shown). 
 A similar pattern of mRNA expression 
was observed for the Fos family members 
implicated by EMSAs in the binding to the 
Rdm2 P2 AP-1 sequence (Fig. 10, A-D).  
Transcript abundances increased by 
approximately 20-fold for c-Fos (Fig. 10A), 
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15-fold for FosB (Fig. 10B) and 10-fold for 
Fra-1 (Fig. 10C) over 1 to 2 h before 
subsequently declining.  Abundances of Fra-2 
did not change significantly (results not 
shown) in accord with the results of supershift 
EMSAs (Fig. 8C).  For c-Fos protein, 
abundance increased by approximately 15-fold 
over the same time period before declining 
(Fig. 10D).  Antibodies against FosB and Fra-
1 were not satisfactory for unequivocal use in 
immunoblotting in our hands.  These results 
suggest that one factor in the increase in 
binding of AP-1 proteins to the Rdm2 P2 
sequence is an increase in their abundances. 
 Effects of Rdm2 on caspase 3 cleavage 
in H2O2-treated cardiac myocytes - Mdm2 and 
its orthologues are generally considered to be 
antiapoptotic.  We examined whether Rdm2 
expression delayed the pro-apoptotic effects of 
oxidative stress in cardiac myocytes using an 
antisense ODN to a region of Rdm2 exon 7 
(Supplemental Material Fig. 2).  This reduced 
H2O2-stimulated expression of Rdm2 protein 
by approximately 75% (Fig. 11A, top panel 
and Fig 11B).  Apoptosis was assessed by 
formation of the 17 kDa active (cleaved) form 
of caspase 3.  H2O2 increased the abundance of 
17 kDa caspase 3 in the absence or presence of 
lipofectin by about 2.5- to 4-fold (Fig. 11A, 
middle panel, Fig. 11C), thus demonstrating 
that, under the conditions used, H2O2 was pro-
apoptotic.  The Rdm2 antisense ODN (but not 
a scrambled ODN) further increased the H2O2-
mediated stimulation of 17 kDa caspase 3 
formation by some 2- to 3.5-fold [depending 
on the value of 17 kDa caspase 3 formation 
(lipofectin, no H2O2, or nonsense 
oligodeoxynucleotide + H2O2 ) used as 
denominator] (Fig. 11A, middle panel, Fig. 
11C).  As judged by immunoblotting for "-
actin, the adherence of the myocytes to the 
culture dishes was unaffected by any treatment 
(Fig. 11A, bottom panel).  These results 
suggest that one role of increased Rdm2 
expression in myocytes exposed to oxidative 
stress is to reduce or delay apoptosis. 
 
DISCUSSION 
 
 The effects of H2O2 on Mdm2 
expression in the heart - The effects of ROS 
generally and H2O2 in particular on Mdm2 
expression in cardiac and non-cardiac cells 
have not been extensively examined 
previously.  In non-cardiac cells, H2O2 
upregulates Mdm2 mRNA and protein 
expression in concert with upregulation of p53 
and the assumption is that induction of p53 
protein is responsible for upregulation of 
Mdm2 (40-42).  However, this may not be 
universal (43).  Of relevance to cardiac 
myocytes, in the H9c2 rat ventricular myoblast 
line, H2O2 (0.4 mM, 24 h) increases Rdm2 
protein abundance (44) whereas, in contrast to 
our microarray data (3,10), Rdm2 transcript 
abundance was reported to decrease in cardiac 
myocytes exposed to H2O2 (0.1 mM, 1 h) (45).  
To study Rdm2 in more detail, we first needed 
to characterize the Rdm2 gene and its 
transcript, and Rdm2 protein using 
bioinformatics approaches (Fig. 1, 
Supplemental Material Figs. 1-3).  The current 
details for Rdm2 mRNA in the NCBI database 
(http://www.ncbi.nlm.nih.gov) are misleading 
as the 75 bp exon 4 has been omitted.  It could 
be argued that this shorter is specific to the rat 
and could arise, for example, by altenative 
splicing.  However, in addition to identifying 
exon 4 in rat ESTs, the reverse primer (Table 
1) used in the experiments described in Fig. 3A 
lies within exon 4 and products of the 
predicted sizes were generated, thus 
establishing that exon 4 is expressed in mature 
Rdm2 mRNA. 
 We showed that Rdm2 transcripts and 
protein were rapidly induced (within 1 - 2  h) 
by H2O2 and that this occurs over the 0.1 - 1 
mM range (Fig. 2, A-E).  At higher 
concentrations, expression declines (Fig. 2, D 
and E).  Rdm2 was not regulated as an 
immediate early gene (Fig. 3, A and B) and the 
upregulation of the transcript did not involve 
transcript stabilization (Fig. 3C).  As in other 
cells (16), constitutive Rdm2 expression 
involved the 5'-P1 promoter, whereas H2O2-
inducible expression was largely regulated 
through the P2 promoter within intron 1 (Fig. 
4, A and B).  Intron 1 contains several potential 
transcription factor binding sites including 
sites for p53, AP-1 and Ets  (Fig. 1), any or all 
of which may be important in inducible 
expression of Rdm2.  
 Induction of p53 by H2O2 in cardiac 
myocytes - At least two studies report that 
H2O2 induced expression of p53 transcripts 
and protein in neonatal rat cardiac myocytes in 
culture (2,45).  Because our original data 
contradicted these studies, we have been 
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encouraged to go to great lengths in order to 
prove that our data are correct.  In addition to 
the antibody (FL-393) we originally used, we 
used two further antibodies (Pab 240 and 
2B2.71) for immunoblotting.  We first 
confirmed the selectivity and specificity of 
these antibodies for p53 by immunoblotting 
commercially-available whole cell extracts of 
293T cells transfected with mouse p53 (Fig. 5, 
A-C).   All three antibodies detected p53 as a 
band that migrated slightly more rapidly that 
the 52 kDa marker (Fig. 5, A-C).  This band 
was absent from the negative control cell line, 
though it should be noted that cross-reacting 
proteins of different apparent molecular 
masses could be detected with two of the 
antibodies including one which migrated with 
the 52 kDa marker (Fig. 5, A, C and D).  
Furthermore, rat p53 (induced by treatment of 
cardiac myocytes with daunorubicin) co-
migrated with murine p53 in the positive 
control cell line (Fig. 5D).  None of the three 
antibodies detected any increase in p53 
expression in cardiac myocytes following 
exposure to H2O2, despite a clear induction 
with daunorubicin (Fig. 6, A-D).  Furthermore, 
we could not detect any induction of p53 by 
H2O2 using EMSAs despite the clear induction 
by daunorubicin of a band which could be 
supershifted with p53 antibodies (Fig. 6, E and 
F).  Thus, we are confident that 0.2 mM H2O2 
does not induce expression of p53 in cardiac 
myocytes and this probably excludes any role 
for p53 in H2O2-induced Rdm2 expression. 
 It is not entirely clear why others have 
detected p53 induction by H2O2 (2,45), but 
there are at least four potential areas of 
concern: (i) the antibody used, (ii) the cell 
extracts used, (iii) the conditions used, and (iv) 
the absence of positive controls for p53.  First, 
both von Harsdorf et al. (2) and Long et al. 
(45) used a monoclonal antibody from 
Calbiochem of which there are currently six 
currently listed 
(http://www.emdbiosciences.com or 
http://www.merckbiosciences.co.uk).  Not 
surprisingly given the time elapsed, none of 
the three authors of Reference (2) could recall 
which antibody was used, and indeed the 
choice may have been limited or nomenclature 
not specified by the supplier at this stage.  In 
the report by Long et al. (45), Dr. José Marín-
García informed us that they had used the 
Calbiochem Ab-4 antibody (cat. no. OP32) 
from the Pab 246 clone, but he now purchases 
this from Santa Cruz Biotechnology Inc. (cat 
no. sc-100).  We found that Pab 246 cross-
reacted with several proteins in the 52 kDa 
region in 293T whole cell extracts (results not 
shown) and we did not use this antibody .  
Secondly, in both reports, whole cell extracts 
of cardiac myocytes were used rather than 
crude nuclear extracts.  Generally, we find that 
whole cell extracts are unsatisfactory for 
detection of nuclear transcription factors by 
immunoblottine, mainly because of cross-
reaction with other proteins.  Indeed, two of 
the three antibodies showed cross-reactivity 
with a band at 52 kDa in 293T whole cell 
extracts (Fig. 5, A, C and D) which was not 
detectable in nuclear extracts from rat cardiac 
myocytes (Fig. 5D and Fig. 6, A-D) but which, 
in the absence of a positive control, could be 
mistaken for p53.  Thirdly, although the 
conditions used by Long et al. (45) (0.1 mM 
H2O2 for 30 min, 1 h or 24 h) resembled our 
own, von Harsdorf et al. (2) used a potentially 
more severe oxidative stress (0.1 mM 
H2O2/0.1 mM Fe2+ for 1 h, followed by further 
culture in H2O2/Fe2+-free medium for up to 23 
h).  The combination of H2O2 and Fe2+ leads to 
a catalytic disproportionation of H2O2 into the 
highly-reactive hydroxyl radical (which is 
toxic and induces a severe oxidative stress), 
and a peroxide radical, and is commonly 
known as the Fenton reaction (Fe2+ + H2O2 6 
Fe3+ + OHC + OH!; Fe3+ + H2O2 6 Fe2+ + 
OOHC + H+).  Fourthly, for both of the 
published studies (2,45), there were no 
positive controls for p53, nor were the 
positions of molecular mass markers included. 
 Regulation of inducible Mdm2 by p53-
independent mechanisms - Expression of the 
Mdm2 gene can also be regulated by p53-
independent mechanisms (19-21).  Thus, point 
mutations in any one of the AP-1, Ets(AP-1) or 
Ets(upstream) elements reduce induction of Mdm2 
expression by oncogenic Ras or Raf in NIH-
3T3 cells (19).  Furthermore, elevated HDM2 
expression in a breast cancer cell line is partly 
dependent on the composite AP-1!Ets(AP-1) 
element (20).  In contrast, up-regulation of 
Mdm2 in certain mouse erythroleukaemia lines 
is partly attributable to increased expression of 
Fli-1 (an Ets family transcription factor) and 
may involve the Ets(upstream) element (21).  
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 Ets family transcription factors 
number >20 members (39) that require a core 
GGA motif for response element recognition 
with slightly varying preferences in the 
flanking sequences (34).  In cardiac myocytes 
exposed to H2O2, constitutive (complex 1) and 
transiently-inducible (complex 2) protein 
binding to the Ets(upstream) element was detected 
by EMSAs (Fig. 7, A and B).  We attempted to 
supershift the Ets(upstream) complexes with 
antibodies to the biologically activated form of 
Elk-1 [phospho-Elk-1(Ser-383)] (the 
orthologous residue in rat Elk-1 is in fact Ser-
382) and to Fli-1but were unsuccessful (results 
not shown).  We consider it unlikely that the 
Ets(upstream) element is significant in Rdm2 
upregulation because (i) the level of complex 1 
does not change and (ii) levels of complex 2 
were returning to zero-time values before any 
significant induction of Rdm2 transcripts or 
Rdm2 protein was detectable (Fig. 2, A-C, and 
F, Fig. 7B).  Equally, we could not obtain any 
convincing evidence that the Ets(AP-1) element 
might be involved.  The EMSA band with the 
Ets(AP-1) probe was not inducible, and was not 
competed by unlabeled probe. 
 We turned our attention to the AP-1 
site.  AP-1 is a heterodimer of Fos and Jun 
family members or possibly a homodimer of 
Jun family members, and it controls the 
transcription of numerous genes (46).  The 
AP-1 complex can either activate or inhibit 
gene expression and its two subunits do not 
necessarily act in concert.  Thus, whereas c-
Fos and FosB act in concert with c-Jun (the 
most powerful transcriptional regulator), c-Jun 
may be antagonized by JunB, and by Fra-1 and 
Fra-2 which do not contain transactivation 
domains.  Furthermore, the transactivating 
activities of AP-1 proteins can be influenced 
by post-translational modification (e.g. 
phosphorylation).  As with Ets transcription 
factors, there is evidence that AP-1 may 
participate in regulation of Mdm2 expression 
(19).  In our study, EMSAs showed specific 
binding of proteins to the Rdm2 AP-1 element 
(Fig. 7C) with a time-course consistent with 
induction of Rdm2 expression (Fig. 2, A-C, 
and Fig. 6D).  c-Jun and JunD bound to the 
probe in unstimulated cells (Fig. 8A).  In cells 
exposed to H2O2, JunB (Fig. 8B) and Fos 
family members (c-Fos, FosB, Fra-1, but not 
Fra-2) were also bound (Fig. 8C).  The binding 
of Fra-1 is a little surprising given that 
expression of Rdm2 is increased but Fra-1 is 
supposed to reduce AP-1-dependent 
stimulation of gene expression (46), and we do 
not have any explanation for this at present.  A 
cocktail of antibodies to c-Jun, JunB, JunD, c-
Fos, FosB and Fra-1 resulted in essentially a 
complete supershift of the complex (Fig. 8D).  
Of the Jun and Fos members mentioned but 
with the exceptions of JunD and Fra-2, 
transcripts (and usually proteins) were induced 
by H2O2 (Figs. 9 and 10) within the time-
period chosen for supershifting (1.5 h).  Using 
ChIP assays, we demonstrated increased 
binding of c-Jun and JunB to an Rdm2 P2 
promoter region encompassing the AP-1 site 
(Fig. 8E).  ChIP assays using antibodies to the 
remaining Fos/Jun proteins were less 
successful, presumably because of their 
inadequacy in immunoprecipitation protocols.  
These results strongly suggest that the Rdm2 
AP-1 element is of significance in the 
upregulation of Rdm2 expression by H2O2, and 
that increased abundances of AP-1 
transcription factors [several of which have 
been confirmed as immediate early genes in 
cardiac myocytes in the context of endothelin 
stimulation (47)] participate in Rdm2 mRNA 
upregulation. 
 H2O2 and ROS are established 
regulators of AP-1 (48).  All of the three major 
MAPK cascades (JNK, ERK1/2, p38-MAPK) 
are activated by H2O2 in cardiac myocytes (49) 
and may influence AP-1 expression and 
activity.  JNKs phosphorylate c-Jun in its 
transactivation domain and increase its 
transactivating activity (46).  In addition, c-
Jun mRNA and protein is upregulated by a 
combination of activation of ERK1/2 (to 
increase transcription of c-Jun) and JNKs (to 
increase protein stability) (50).  Thus, H2O2-
mediated stimulation of MAPK cascades 
might be a factor in the upregulation of AP-1 
transcription factor levels and activities in our 
study. 
 Cardioprotective effects of Mdm2 - 
p90-Mdm2 is present in whole murine heart in 
greater abundance than p76-Mdm2 (though 
both at much lower abundances than in other 
tissues such as testis) (23).  Cardioselective 
deletion of Mdm2 is embryonically-lethal and 
this lethality can be rescued by deletion of p53 
(51), thus emphasizing the importance of 
Mdm2 in limiting p53 expression during 
cardiac development.  In the developed heart, 
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the role of Mdm2 in cardioprotection is 
implicit from a number of studies.  Increasing 
Mdm2 abundance by overexpression of the 
transcriptional coactivator p300 protects 
against apoptosis induced by the cardiotoxic 
anthracycline doxorubicin in mice in vivo (52).  
Cardiospecific overexpression of insulin-like 
growth factor 1 increases the association 
between p53 and Mdm2 thus reducing the 
binding of p53 to the promoter of the 
proapototic bax gene (53).  The growth factor 
also reduces mechanical strain-induced 
apoptosis in isolated cardiac myocytes, one 
possible mechanism involving an Rdm2-
mediated reduction in p53 abundance (54).  
Overexpression of Mdm2 also protects against 
the pro-apoptotic effects of hypoxia and 
inhibition of the p53-Rdm2 interaction 
increases the sensitivity to hypoxia (55).  
Furthermore, reduced expression of Mdm2 
increases the susceptibility of the isolated 
heart to injury induced by ischemia and 
reperfusion (55).   
 In general agreement with these earlier 
studies, our studies here suggest that the 
induction of Rdm2 expression by H2O2 
represents a cytoprotective defence against 
oxidative stress in the cardiac myocyte (Fig. 
11).  Thus, diminished H2O2-mediated 
induction of Rdm2 using an antisense ODN to 
Rdm2 promoted caspase 3 activation (Fig. 11, 
A and C).  It is pertinent to ask how Rdm2 can 
decrease apoptosis, given that H2O2 did not 
induce p53 expression (Fig. 6).  One 
explanation may be that other pro-apoptotic 
proteins expressed in myocytes are inhibited 
or downregulated by Rdm2.  Precedents for 
this exist.  For example, treatment of p53-null 
neuroblastoma cells with the HDM2-protein 
interaction inhibitor, nutlin-3, stimulates 
apoptosis by inhibiting the interaction with the 
p53-related protein, p73 (56).  It should 
perhaps also be noted that inhibition of HDM2 
is currently under intensive investigation as a 
chemotherapeutic intervention (57).  From the 
results of our own and other studies, such 
therapies may decrease cardiac myocyte 
survival, particularly under conditions of 
oxidative stress which probably occur during 
myocardial ischemia and heart failure. 
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trans-epoxy-succinyl-l-leucylamido-(4-guanidino)-butane; EMSA, electrophoretic mobility shift 
assay; ERK, extracellular signal-regulated kinase; Gapd, glyceraldehyde 3-phosphate dehydrogenase; 
JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; Mdm2, mouse double 
minute 2 (HDM2 and Rdm2, Homo sapiens and rat orthologues of Mdm2, respectively); MZF-1, 
myeloid zinc finger protein-1; ODN, oligodeoxynucleotide; PBS, phosphate-buffered saline; PMSF, 
phenyl methyl sulfonyl fluoride; ROS, reactive oxygen species; RT-qPCR and RT-sqPCR, reverse 
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specifically to the mouse or to the three orthologues generally. 
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FIGURE LEGENDS 
 
FIG. 1.  The deduced structure of the 5' region of the Rdm2 gene.  Further details are provided in 
the Results section.  The complete deduced sequence of mature Rdm2 mRNA is shown in 
Supplemental Material Fig. 2.  The numbering refers to the positions of the nucleotides in the gene 
sequence.  The positions of the primers used to determine P1/P2 promoter usage in exons 1, 2 
(forward primers F1 and F2, respectively) and in exon 4 are indicated, as are the two alternative 
translational initiation codons [ATG(1) for p90-Rdm2, ATG(2) for p76-Rdm2].  The consensus 
sequences for the transcription factor response elements are: MZF-1, AGTGGGGA or the more-
extended CGGGNGAGGGGGAA (36); Ets, C(A/C)GGA(A/T)G(C/T) (34); AP-1, TGA(C/G)TCA 
(33); NF-E2, (C/T)TGCTGA(C/G)TCA(C/T) (35); p53, two 
(A/G)(A/G)(A/G)C(A/T)(A/T)G(C/T)(C/T)(C/T) elements separated by 0 to 13 nucleotides (31).  The 
positions of the response elements and the 5' to 3' directions applicable are marked by arrows.  The 
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positions of the primers used in the chromatin immunoprecipitation studies of the AP-1 response 
element are indicated by underlying asterisks (see also Table 1). 
 
FIG. 2.  Expression of Rdm2 transcripts and protein in cardiac myocytes exposed to H2O2.   
RNA or protein was extracted and Rdm2 mRNA or protein abundances were determined by RT-
sqPCR, RT-qPCR or immunoblotting as described under ‘Experimental Procedures’.  (A,B,C) 
Myocytes were exposed to 0.2 mM (A,B) or 1 mM (C) H2O2 for the times indicated and Rdm2 
transcripts measured by RT-sqPCR (A) or RT-qPCR (B,C). (D,E) Dependence of Rdm2 mRNA 
expression at 2 h [(D), RT-sqPCR; (E), RT-qPCR] or 1 h (E, RT-qPCR) on H2O2 concentration.  No 
RT: as a control for genomic contamination, the RT step was omitted.  (F,G) Rdm2 protein 
abundances were determined by immunoblotting of whole cells extracts at the times indicated.  
Primary antibody dilution: both at 1/750.  Representative primary data are shown and the quantified 
results are expressed as means ± SEM for at least 3 independent observations on separate preparations 
of myocytes. 
 
FIG. 3.  Rdm2 is not and immediate early gene, nor is Rdm2 mRNA stabilized by H2O2.  (A,B) 
Cardiac myocytes were pretreated with cycloheximide (CHX, 20 :M) for 30 min, then exposed 
additionally to 0.2 mM H2O2 for 2 h (A, RT-sqPCR) or 1h (B, RT-qPCR).  (C) H2O2 (0.2 mM) 
exposure does not affect Rdm2 transcript stability.  Myocytes were exposed (!) or not exposed (•) to 
0.2 mM H2O2 for 2 h, then to 4 :M actinomycin D for the times indicated, followed by RT-sqPCR.  
Results were fitted to monophasic exponential decay curves.  Representative primary data are shown 
and the quantified results are expressed as means ± SEM for 3-4 independent observations on separate 
preparations of myocytes.  Statistical significance: *, P<0.001 by one-way ANOVA with Tukey’s 
multiple comparison test. 
 
FIG. 4.  Promoter usage for Rdm2 expression.  (A) Cardiac myocytes were exposed to or not 
treated with 0.2 mM H2O2 for 2 h.  RNA was extracted and RT-sqPCR was used with a reverse primer 
in exon 4 and forward primers lying in exon 1 (primer F1) to assess P1 promoter usage (long product, 
333 bp) or exon 2 (primer F2) to assess combined P1 and P2 promoter usage (short product, 220 bp) 
(Fig. 1 and Table 1).  Representative primary data are shown and the quantified results are expressed 
as means ± SEM for 6 independent observations on separate preparations of myocytes.  Statistical 
significance versus control: *, P<0.01 by one-way ANOVA with Tukey’s multiple comparison test.  
(B) 5' RACE for Rdm2 transcripts in myocytes exposed or not exposed to 0.2 mM H2O2 for 2 h.  The 
theoretical lengths of amplicon A (from P1 promoter use) and amplicon B (from P2 promoter use) are 
332 and 162 bp, respectively. 
 
FIG. 5.  Characterization of p53 antibodies.  Extracts of 293T cells that had either been transfected 
with mouse p53 (positive control) or not transfected (negative control) were examined by SDS-PAGE 
and immunoblotting with (A) FL-393 antibody, (B) Pab 240 antibody, or (C and D) 2B2.71 antibody, 
all at 1/1000 dilution.  In (D), a crude nuclear extract from cardiac myocytes exposed to 0.5 :M 
daunomycin for 6.5 h was included.  The position of the 52 kDa molecular mass marker is indicated. 
 
FIG. 6.  H2O2 does not induce expression of p53 in cardiac myocytes.  Myocytes were exposed to 
0.2 mM (A-F) or 0.5 mM (C) H2O2 for the times indicated or to daunorubicin.  (A-D) Immunoblots of 
crude nuclear extracts from myocytes.  Blots were probed with the p53(FL-393) antibody (A) at a 
dilution of 1/1200, with the 2B2.71 antibody (B,C) at a dilution of 1/1000, or with the Pab 240 
antibody (D) at a dilution of 1/1000.  For 2B2.71 and Pab 240, an amplification step with an rabbit 
anti-mouse antibody and a goat anti-rabbit horseradish peroxidase-conjugated tertiary antibody was 
used.  (E) EMSAs of crude nuclear extracts were carried out with a p53 consensus binding sequence 
probe.  (F) Myocytes were exposed to 0.5 :M daunorubicin for 7.5 h and supershift EMSAs were 
carried out with the antibodies indicated. Representative primary data are shown for 3 independent 
observations on separate preparations of myocytes. 
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FIG. 7.  Binding of proteins to the Ets(upstream) and AP-1 response elements in the Rdm2 P2 
promoter as assessed by EMSAs.  Cardiac myocytes were exposed to 0.2 mM H2O2 as indicated and 
crude nuclear extracts prepared.  Sequences of probes are given in Table 2.  (A,C) EMSAs using the 
Ets(upstream) probe (A) or the AP-1 probe (C).  Binding specificities were assessed using unlabelled 
probe.  Two specific complexes (1 and 2) were detected with the Ets(upstream) probe (A) and one was 
detected for the AP-1 probe (C).  (B,D) Time courses of binding to the Ets(upstream) probe (B) or the AP-
1 probe (D).  Representative primary data are shown and the quantified results are expressed as means 
± SEM for 3-5 independent observations on separate preparations of myocytes. 
 
FIG. 8.  Binding of AP-1 proteins to the AP-1 response element in the Rdm2 P2 promoter as 
assessed by supershift EMSAs or ChIP assays.  Cardiac myocytes were exposed to 0.2 mM H2O2 
as indicated and crude nuclear extracts prepared.  (A-D) Supershift EMSAs were performed using the 
antibodies indicated.  SS: supershifted complex.  (E) ChIP assays using c-Jun or JunB antibodies, as 
indicated.   Representative primary data are shown and the quantified results are expressed as means ± 
SEM for 3 independent observations on separate preparations of myocytes.  Statistical significance 
versus control: *, P<0.05 by an unpaired two-way Student’s t test. 
 
FIG. 9.  Expression of c-Jun and JunB transcripts and proteins.  Cardiac myocytes were exposed 
to 0.2 mM H2O2 as indicated.  mRNA abundance was determined by RT-sqPCR, and protein 
abundance in crude nuclear extracts was assessed by immunoblotting.  (A,B) Expression of c-Jun (A) 
and JunB (B) transcripts.  No RT: no reverse transcriptase step.  (C-F) Expression of c-Jun (C,D) and 
JunB (E,F) proteins.  Antibody dilutions: c-Jun, 1/750; JunB, 1/5000.  Representative primary data are 
shown and the quantified results are expressed as means ± SEM for 3-4 independent observations on 
separate preparations of myocytes. 
 
FIG. 10.  Expression of c-Fos, Fos-B and Fra-1 transcripts and c-Fos protein.  Cardiac myocytes 
were exposed to 0.2 mM H2O2 as indicated.  mRNA abundance was determined by RT-sqPCR, and 
protein abundance in crude nuclear extracts was assessed by immunoblotting.  (A-C) Expression of c-
Fos (A), FosB (B) and (C) Fra-1 transcripts assessed by RT-sqPCR.  No RT: no reverse transcriptase 
step.  (D) Expression of c-Fos protein.  Antibody dilution for c-Fos: 1/20,000.  Representative primary 
data are shown and the quantified results are expressed as means ± SEM for 3-4 independent 
observations on separate preparations of myocytes. 
 
FIG. 11.  ‘Knock-down’ of Rdm2 protein in cardiac myocytes with an antisense ODN to the 
Rdm2 transcript increases H2O2-induced activation of caspase 3.  AS, antisense ODN; NS, 
scrambled ODN.  (A) Abundances of Rdm2 (top panel), active caspase 3 (middle panel) and 
sarcomeric "-actin (bottom panel) in whole cell extracts were assessed by immunoblotting.  (B,C) 
Quantification of (B) Rdm2 or (C) active caspase 3 abundances.   Antibody dilutions: Rdm2, 1/500; 
caspase 3, 1/1000; "-actin, 1/2000.  Representative primary data are shown and the quantified results 
are expressed as means ± SEM for 4 independent observations on separate preparations of myocytes.  
Statistical significance versus control: *, P<0.05; **, P<0.001 by one-way ANOVA with Tukey’s 
multiple comparison tes 
TABLE 1.  Details of RT-sqPCR/qPCR primers used.  For the Rdm2 transcript, the numbering used refers to the deduced sequence shown in 
Supplemental Material Fig. 2.  For Rdm2, primers for Rdm2(A) were used for sqPCR analysis of general Rdm2 expression, primers for Rdm2(B) 
were used for qPCR analysis of general Rdm2 expression, primers for Rdm2(C) and Rdm2(D) were used to investigate P1/P2 promoter usage 
(sqPCR), primers for Rdm2(E) were used for 5' RACE (sqPCR), and primers for Rdm2(F) were used for ChIP analysis (sqPCR).  The sequence 
of Rdm2 intron 1, in which the primers used for chromatin immunoprecipitation lie, is shown in Fig. 1.  The predicted rat FosB transcript 
sequence (NM_001013146.1) is truncated at its 3' end.  The rat FosB  gene is located on chromosome 1 at 78668523..78673784 (RGSC genome 
assembly v3.4).  The RT-sqPCR product corresponds to 78667636..78667773, sequence: 
ACCCCTGTGCAGTATTATGCCATGTCCCTCTCACCCCCACGGGCAACCCAGGCGCCCTTGGCCGTCCTCGTTGGGCCTTTCTGGT
TTTGGGCAGCAGGGGGCGCTGCGACGCCCGTCTTGCTGGAGCGCTTTATACTG (primers underlined and emboldened).  In contrast, 
the mouse FosB mRNA sequence (NM_008036.2) is more extended and contains the PCR sequence described.  The PCR sequence identifies 
two rat ESTs (C06882.1, CB747983.1) and these lie 3' to the predicted rat FosB transcript.  In addition, the two rat ESTs correspond to the 3' 
untranslated region of the mouse FosB mRNA. 
 
Transcript 
for 
Forward primer (5'→3') Exon Reverse primer (5'→3') Exon Amplicon 
identity or 
transcript 
accession no. 
Position of 
primers in 
mRNA 
Product 
length 
(bp) 
No. of 
cycles 
 used 
Rdm2 (A) ATCCAGCTTCTCTCTGAACG 
12 
AGACTAAGACAATGCTCCGG 
12 
Supplemental 
Material Fig. 1 
1504-1802 
299 27 
Rdm2 (B) TCCGACCACCGTGCTTCT 
2 
TCGGTAGACACAGACATGTTGGTA 
3 
Supplemental 
Material Fig. 1 
211-279 
69 
--- 
Rdm2 (C) TCGCTTCGCTCGACCTCC 1 CTCTTTCATAGTGTAAATATCTTT 4 Fig. 1 71-403 333 27 
Rdm2 (D) AGCGGAGACGGACACACC 2 CTCTTTCATAGTGTAAATATCTTT 4 Fig. 1 184!403 220 27 
Rdm2 (E) AAGCAGTGGTATCAACGCAGA
GTACGCGGG 
N/A TCTGTGAGGTGCCTGCAGCACCCTCG
GTAGACAC  3 
5' RACE tag N/A-302 332 (P1) 
162 (P2) 35 
Rdm2 (F) CAGGGGTCGGGGAGGTAA Intron 1 TTAGCTCCTCCAACAGCCAA Intron 1 Fig. 1 Intron 1 144 35 
Gapd ACCACAGTCCATGCCATCAC 
6 
TCCACCACCCTGTTGCTGTA 
8 
NM_17008.2 
NM_17008.3 
1369-1820 
596-1047 452 20 
p53 TTGAGGTTCGTGTTTGTGCC 7 CACGGGCATCCTTTAATTCC 9 NM_030989.3 934-1188 255  
c-Jun ATGACTGCAAAGATGGAAACG N/A TATTCTGGCTATGCAGTTCAG N/A* NM_021835         859-1234 376 24 
JunB ATCACGACGACTCATACGCA N/A TGGAGGCTAGCTTCAGAGAT N/A* NM_021836         299-523 225 25 
JunD ATGGAAACGCCCTTCTATGG N/A CTTTCTTCAGCATGCTGCTC N/A* NM_138875         264-420 157 28 
c-Fos AGTGGTGAAGACCATGTCAG 
2 
AATGTTCTTGACCGGCTCCA 
4 
NM_22197.1 
NM_22197.2 
464-911 
482-929 448 25 
FosB ACCCCTGTGCAGTATTATGC  CAGTATAAAGCGCTCCAGCA See Table 1 Legend 138 27 
Fra-1 AATTGCAGTGGATGGTGCAG 2 ACTTAGCAGCTGCTAGCTTG 3 NM_012953         377-595 219 26 
Fra-2 AATCAACGCCATCACCACCA 2 GGTGGTACCAATGGTCTTGA 2 NM_012954         150-330 181 26 
 
TABLE 2.  Sequences of EMSA probes.  See Fig. 1 for details of position in the Rdm2 gene and its intron 1.  p53 EMSAs, a consensus p53 
probe was used. 
 
 
EMSA Probe for EMSA Probe (5'→3') Position 
in gene 
Position 
in intron 1
Mutant EMSA Probe (5'→3') 
Rdm2 AP-1 GCCTAGTTGACTCAGCTTTTC 539!559 369-389 GCCTAGTTGACTTGGCTTTTC 
Rdm2 Ets(upstream) GGACGTGGCTTCCGGGACGGGT 504!525 334-355 GGACGTGGATTCCAGGACGGGT 
Rdm2 Ets(AP-1) GACTCAGCTTTTCCTGTGGGGCTGG 547!571 277-301 GACTCAGCTTTTCCCGGGGGGCTGG 
Rdm2 MZF-1 ATGGAGGGAGGGGAGAGGAG 384-403 214-233 ATGGAGGGAAGGTAGAGGAG 
p53 response element TACAGAACATGTCTAAGCATGCTGGGGACT N/A N/A N/A 
 
1 170
Exon 1 Exon 2 Exon 3 Exon 4
665 737 910 994 54375363
ATG(2)ATG(1)
171 GTACCCGCCA GGAGCGACGC GACGTGCGGG GTTGGGCGGT GGCGAGTTCT GATCATTCCC
231 GAGTCCTCTG GGGCCCACTC GCAGCCCGAG ACGGCTCGCG GGGTCGCGGG GCGACGGTTT
291 GTTGGCGCCG GGCCATGATG CCCTTATTCA TCAGGGTGAG GTGGGGGGGT CTGGGTTAAC
411 GGGGTCTCCC GGCAGGCCCC GCGCCCGGGG GCGGCTCCGG GGTCGCGCTG GGCTCACTGC
351 ACAGCGCACG CGCGGAAGAG GATGACGGGG GTAATGGAGG GAGGGGAGAG GAGAAGAGCC
MZF-1
651 GCTCGTTTCC GCAG
471 AGGGGTCGGG GAGGTAACAG GTGCCTGGTG GTGGGACGTG GCTTCCGGGA CGGGTGGGAC
Ets(upstream)
531 TGGGCTGTGC CTAGTTGACT CAGCTTTTCC TGTGGGGCTG GTCAAGTTAG GACACGTTCA
AP-1
NF-E2
Ets(AP-1) p53(seq. A)
591 GCGTTGGCTG TTGGAGGAGC TAAGTCCTGA CATGTCTCCA GCTGAGGCTA TTTAAACCCT
p53(seq. B) Putative
TATA box
Intron 1
TCGCTTCGCTCGACCTCC
Exon 1 forward
primer F1(71-88)
AGCGGAGACGGACACACC
Exon 2 forward
primer F2 (678-695)
CTCTTTCATAGTGTAAATATCTTT
Exon 4 reverse
primer (5414-5437)
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SUPPLEMENTAL MATERIAL 
 
Supplemental Material FIG. 1.  Alignment (ClustalW2) of the amino acid sequences of 
Mdm2 (NP_034916.1) and its human orthologue HDM2 (NP_002383.2) and the deduced 
amino acid sequence of the rat orthologue of Mdm2 (Rdm2) obtained from the predicted 
nucleotide sequence of the Rdm2 transcript (see Supplemental Material Fig. 2).  The 
non-conserved N-terminal hexapeptide extension in HDM2, which is often ignored for the 
purposes of numbering HDM2 residues, is underlined. 
 
Supplemental Material FIG. 2. Alignment (ClustalW2) of the Mdm2 transcript 
NM_010786.3 and the deduced sequence of the 2930 nucleotide Rdm2 transcript.  The 
genomic sequence (T in place of U) is shown.  The transcript is encoded by 12 exons as 
follows: exon1, nucleotides 1-170; exon 2, nucleotides 171-243; exon 3, nucleotides 244-328; 
exon 4, nucleotides 329-403; exon 5, nucleotides 404-537; exon 6, nucleotides 538-587; exon 
7, nucleotides 588-646; exon 8, nucleotides 647-743; exon 9; nucleotides 744-892; exon 10, 
nucleotides 893-1048; exon 11, nucleotides 1049-1126; exon 12, nucleotides 1127-2930.  
Exon boundaries are indicated by highlighting in light blue (start) and yellow (end).  Primer 
sequences are annotated as given in Table 1.  Other features are highlighted and annotated.  
The translational initial codon for p90-Rdm2 open reading frame (ORF) is at nucleotides 248-
250 (in exon 3) and that for the p76-Rdm2 is at nucleotides 395-397 (in exon 4).  In addition, 
there are two short upstream ORFs (uORFs) in exon 1.  These are out-of-phase with the 
initiation codon of uORF2 overlapping with the termination codon of uORF1 in an ATGA 
sequence at nucleotides 138 to 141.  The Rdm2 termination codon is at nucleotides 1697-
1699.  There is a putative AU-rich instability signal at nucleotides 2072-2085 and a putative 
polyadenylation signal at nucleotides 2906-2911.  ODN, oligodeoxynucleotide. 
 2
Supplemental Material FIG. 3.  Alignment of intron 1 sequences from Mdm2, Rdm2 and 
HDM2.  Features are highlighted and annotated.  The four response elements highly 
conserved in intron 1 of the Rdm2, Mdm2 and HDM2 genes (the two p53 response elements 
and the composite AP-1/Ets sequence) are encompassed by boxes. The features of the intron 1 
regions are described in more detail in the full text.  In addition to these, the HDM2 intron 1 
contains five non-conserved GGGGC repeats at bases 112-144 immediately upstream of an E-
box (ACGTG) which are important in constitutive expression from the P2 promoter under 
some circumstances (1).  RE, response element. 
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Rdm2  ------MCNTNMSVSTEGAAGTSQIPASEQETLVRPKPLLLKLLKSVGAQKDIYTMKEII 54 
Mdm2  ------MCNTNMSVSTEGAASTSQIPASEQETLVRPKPLLLKLLKSVGAQNDTYTMKEII 54 
HDM2  MVRSRQMCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVL 60 
            ********.*:**. *****************************:* *****:: 
 
Rdm2  FYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVVVSQQ- 113 
Mdm2  FYIGQYIMTKRLYDEKQQHIVYCSNDLLGDVFGVPSFSVKEHRKIYAMIYRNLVAVSQQ- 113 
HDM2  FYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQE 120 
      **:***************************:***************:*******.*.**  
 
Rdm2  --DSGTSPSESRCQPEGGSDLKDPVQASQEEKPSSSDVVSRPSTSSRRRAISETEENTDE 171 
Mdm2  --DSGTSLSESRRQPEGGSDLKDPLQAPPEEKPSSSDLISRLSTSSRRRSISETEENTDE 171 
HDM2  SSDSGTSVSENRCHLEGGSDQKDLVQELQEEKPSSSHLVSRPSTSSRRRAISETEENSDE 180 
        ***** **.* : ***** ** :*   *******.::** *******:*******:** 
 
Rdm2  LPGERQRKRHRA----LSFDESLGLCVLREICCE-----RSSSSEATDTPSHQDLDDGVS 222 
Mdm2  LPGERHRKRRRS----LSFDPSLGLCELREMCSGGSSSSSSSSSESTETPSHQDLDDGVS 227 
HDM2  LSGERQRKRHKSDSISLSFDESLALCVIREICCE-----RSSSSESTGTPSNPDLDAGVS 235 
      *.***:***:::    **** **.** :**:*.       *****:* ***: *** *** 
 
Rdm2  DHSADCLDQDSVSDQFSVEFEVESLDSEDYSLSDEGHELSDEDDEVYRVTVYQAGESDAD 282 
Mdm2  EHSGDCLDQDSVSDQFSVEFEVESLDSEDYSLSDEGHELSDEDDEVYRVTVYQTGESDTD 287 
HDM2  EHSGDWLDQDSVSDQFSVEFEVESLDSEDYSLSEEGQELSDEDDEVYQVTVYQAGESDTD 295 
      :**.* ***************************:**:**********:*****:****:* 
 
Rdm2  SFEGDPEISLADYWKCTSCNEMNPPLPSHCNRCWTLRENWLPDDKGKDKVEISEKAKLES 342 
Mdm2  SFEGDPEISLADYWKCTSCNEMNPPLPSHCKRCWTLRENWLPDDKGKDKVEISEKAKLEN 347 
HDM2  SFEEDPEISLADYWKCTSCNEMNPPLPSHCNRCWALRENWLPEDKGKDKGEISEKAKLEN 355 
      *** **************************:***:*******:****** *********. 
 
Rdm2  SDQAEEGLDVPDGKKVTEDDAKESSAE-DSEEKVAQMLLSQESDDYSQPSTSSSIVYSSQ 401 
Mdm2  SAQAEEGLDVPDGKKLTENDAKEPCAEEDSEEKAEQTPLSQESDDYSQPSTSSSIVYSSQ 407 
HDM2  STQAEEGFDVPDCKKTIVNDSRESCVE-ENDDKITQASQSQESEDYSQPSTSSSIIYSSQ 414 
      * *****:**** **   :*::*...* :.::*  *   ****:***********:**** 
 
Rdm2  ESGKELK-EDTQDKEESMESSFSLNAIEPCVICQGRPKNGCIVHGKTGHLMSCFTCAKKL 460 
Mdm2  ESVKELK-EETQDKDESVESSFSLNAIEPCVICQGRPKNGCIVHGKTGHLMSCFTCAKKL 466 
HDM2  EDVKEFEREETQDKEESVESSLPLNAIEPCVICQGRPKNGCIVHGKTGHLMACFTCAKKL 474 
      *. **:: *:****:**:***:.****************************:******** 
 
Rdm2  KKRNKPCPVCRQPIQMIVLTYFN 483 
Mdm2  KKRNKPCPVCRQPIQMIVLTYFN 489 
HDM2  KKRNKPCPVCRQPIQMIVLTYFP 497 
      ********************** 
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  1 
Rdm2  TGCTTTGTTAACGGGGCCTCCGAAGCCGGGGTAGCCTAGGAGCGGCCGCGTTCTACGTCA 60 
Mdm2  -GCTTTGTTAACGGGGCCTCCGGGGCCAGCGTAGCCTAGGAGCGGCCG-GTGAGGAGCC- 57 
       *********************  *** * ****************** **     * *  
      Forward primer Rdm2(C)    uORF1 
Rdm2  GGAGCCGCTGTCGCTTCGCTCGACCTCCCGAGCGAA-ATGGTCTCTCAAGTCCCGGCCAC 119 
Mdm2  ---GCCGCCTTCTCGTCGCTCGAGCTCTGGAGCGACCATGGTCGCTCAGGCCCCGGCCGC 114 
         *****  ** * ******** ***  ******  ****** **** * ******* * 
        uORF2       12 
Rdm2  CGGGCCTCCGCGCTCCCCATGAAGGGTCGGAGGCCGCGCGGGGAGTAGCAGCGGTCTGC- 178 
Mdm2  GGGGCCTCCGCGCTCCCCGTGAAGGGTCGGAAGATGCGCGGGAAGTAGCAGCCGTCTGCT 174 
       ***************** ************ *  ******* ********* ******  
    Forward primer Rdm2(D)             Forward primer Rdm2(B)   
Rdm2  AGGCGAGCGGAGA------CGGACACACCGGGGA---CCTCTCCGACCACCGTGCTTCTG 229 
Mdm2  GGGCGAGCGGGAGACCGACCGGACACCCCTGGGGGACCCTCTCGGATCACCGCGCTTCTC 234 
       *********         ******* ** ***    ****** ** ***** ******  
                         
       23   p90-Rdm2 ORF  Reverse primer Rdm2(E) 
Rdm2  CTGCGCGCCTCCAGGCCAATGTGCAATACCAACATGTCTGTGTCTACCGAGGGTGCTGCA 289 
                                TACCAACATGTCTGTGTCTACCGA 
                                Reverse primer Rdm2(B) 
 
Mdm2  CTGCGGGCCTCCAGGCCAATGTGCAATACCAACATGTCTGTGTCTACCGAGGGTGCTGCA 294 
      ***** ****************************************************** 
            34 
Rdm2  GGCACCTCACAGATTCCAGCGTCGGAACAAGAGACTCTGGTTAGACCAAAACCATTGCTT 349 
Mdm2  AGCACCTCACAGATTCCAGCTTCGGAACAAGAGACTCTGGTTAGACCAAAACCATTGCTT 354 
       ******************* *************************************** 
          p76-Rdm2 ORF 
        Reverse primer Rdm2(C)/Rdm2(D) 45 
Rdm2  TTGAAGTTGTTAAAGTCTGTTGGAGCACAAAAAGATATTTACACTATGAAAGAGATTATA 409 
Mdm2  TTGAAGTTGTTAAAGTCCGTTGGAGCGCAAAACGACACTTACACTATGAAAGAGATTATA 414 
      ***************** ******** ***** ** * ********************** 
 
Rdm2  TTTTATATTGGACAGTATATTATGACTAAAAGATTATATGATGAGAAGCAGCAGCACATT 469 
Mdm2  TTTTATATTGGCCAGTATATTATGACTAAGAGGTTATATGACGAGAAGCAGCAGCACATT 474 
      *********** ***************** ** ******** ****************** 
 
Rdm2  GTGTATTGCTCAAATGATCTCCTAGGAGATGTGTTCGGAGTCCCAAGTTTCTCTGTGAAG 529 
Mdm2  GTGTATTGTTCAAATGATCTCCTAGGAGATGTGTTTGGAGTCCCGAGTTTCTCTGTGAAG 534 
      ******** ************************** ******** *************** 
     56           67 
Rdm2  GAGCACAGGAAAATATATGCAATGATCTACAGAAACTTAGTGGTTGTAAGTCAACAAGAC 589 
Mdm2  GAGCACAGGAAAATATATGCAATGATCTACAGAAATTTAGTGGCTGTAAGTCAGCAAGAC 594 
      *********************************** ******* ********* ****** 
      Antisense ODN target      78 
Rdm2  TCTGGAACATCGCCGAGTGAGAGCAGATGTCAGCCTGAAGGTGGGAGTGACCTGAAGGAC 649 
Mdm2  TCTGGCACATCGCTGAGTGAGAGCAGACGTCAGCCTGAAGGTGGGAGTGATCTGAAGGAT 654 
      ***** ******* ************* ********************** ********  
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Rdm2  CCCGTGCAAGCATCACAAGAAGAGAAACCTTCATCTTCTGATGTAGTTTCTAGACCATCT 709 
Mdm2  CCTTTGCAAGCGCCACCAGAAGAGAAACCTTCATCTTCTGATTTAATTTCTAGACTGTCT 714 
      **  *******  *** ************************* ** *********  *** 
           89  
Rdm2  ACCTCATCTAGAAGGAGAGCAATTAGTGAAACAGAAGAGAACACAGATGAACTACCTGGG 769 
Mdm2  ACCTCATCTAGAAGGAGATCCATTAGTGAGACAGAAGAGAACACAGATGAGCTACCTGGG 774 
      ****************** * ******** ******************** ********* 
 
Rdm2  GAACGACAGAGGAAGCGCCACAGAGCCCTGTCCTTTGATGAGAGCCTGGGTCTGTGTGTG 829 
Mdm2  GAGCGGCACCGGAAGCGCCGCAGGTCCCTGTCCTTTGATCCGAGCCTGGGTCTGTGTGAG 834 
      ** ** **  ********* ***  **************  ***************** * 
 
Rdm2  CTCAGGGAGATATGCTGTGAA---------------AGAAGCAGCAGCAGCGAGGCCACA 874 
Mdm2  CTGAGGGAGATGTGCAGCGGCGGCAGCAGCAGCAGTAGCAGCAGCAGCAGCGAGTCCACA 894 
      ** ******** *** * *                 ** *************** ***** 
       910 
Rdm2  GACACCCCCTCACATCAGGATCTTGATGATGGCGTAAGTGACCATTCTGCTGATTGCCTG 934 
Mdm2  GAGACGCCCTCGCATCAGGATCTTGACGATGGCGTAAGTGAGCATTCTGGTGATTGCCTG 954 
      ** ** ***** ************** ************** ******* ********** 
 
Rdm2  GATCAGGATTCAGTTTCTGATCAATTCAGTGTAGAATTTGAAGTTGAGTCTCTTGACTCA 994 
Mdm2  GATCAGGATTCAGTTTCTGATCAGTTTAGCGTGGAATTTGAAGTTGAGTCTCTGGACTCG 1014 
      *********************** ** ** ** ******************** *****  
              1011 
Rdm2  GAAGATTACAGCCTGAGTGATGAAGGGCATGAGCTCTCAGATGAGGATGATGAGGTCTAT 1054 
Mdm2  GAAGATTACAGCCTGAGTGACGAAGGGCACGAGCTCTCAGATGAGGATGATGAGGTCTAT 1074 
      ******************** ******** ****************************** 
 
Rdm2  CGGGTCACAGTCTATCAGGCAGGAGAAAGCGATGCAGACTCTTTTGAGGGAGATCCTGAA 1114 
Mdm2  CGGGTCACAGTCTATCAGACAGGAGAAAGCGATACAGACTCTTTTGAAGGAGATCCTGAG 1134 
      ****************** ************** ************* ***********  
    1112 
Rdm2  ATTTCCTTAGCTGACTATTGGAAATGCACCTCGTGCAATGAAATGAATCCTCCCCTTCCA 1174 
Mdm2  ATTTCCTTAGCTGACTATTGGAAGTGTACCTCATGCAATGAAATGAATCCTCCCCTTCCA 1194 
      *********************** ** ***** *************************** 
 
Rdm2  TCACACTGCAACAGATGTTGGACCCTTCGTGAGAACTGGCTTCCAGACGATAAGGGGAAA 1234 
Mdm2  TCACACTGCAAAAGATGCTGGACCCTTCGTGAGAACTGGCTTCCAGACGATAAGGGGAAA 1254 
      *********** ***** ****************************************** 
 
Rdm2  GATAAAGTGGAAATTTCTGAAAAAGCCAAACTGGAAAGCTCAGATCAGGCAGAAGAAGGC 1294 
Mdm2  GATAAAGTGGAAATCTCTGAAAAAGCCAAACTGGAAAACTCAGCTCAGGCAGAAGAAGGC 1314 
      ************** ********************** ***** **************** 
 
Rdm2  TTAGATGTGCCTGATGGCAAAAAAGTGACAGAGGATGATGCTAAGGAGTCATCTGCTGAG 1354 
Mdm2  TTGGATGTGCCTGATGGCAAAAAGCTGACAGAGAATGATGCTAAAGAGCCATGTGCTGAG 1374 
      ** ********************  ******** ********** *** *** ******* 
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Rdm2  GA---TAGCGAGGAAAAAGTGGCCCAGATGCTCCTGTCACAGGAGAGTGACGACTATTCC 1411 
Mdm2  GAGGACAGCGAGGAGAAGGCCGAACAGACGCCCCTGTCCCAGGAGAGTGACGACTATTCC 1434 
      **    ******** ** *  *  **** ** ****** ********************* 
 
Rdm2  CAGCCGTCGACTTCCAGTAGCATTGTTTACAGCAGCCAAGAAAGTGGCAAAGAGTTGAAG 1471 
Mdm2  CAACCATCGACTTCCAGCAGCATTGTTTATAGCAGCCAAGAAAGCGTGAAAGAGTTGAAG 1494 
      ** ** *********** *********** ************** *  ************ 
 
         Forward primer Rdm2(A) 
Rdm2  GAGGACACACAAGACAAAGAGGAAAGTATGGAATCCAGCTTCTCTCTGAACGCCATCGAG 1531 
Mdm2  GAGGAAACGCAGGACAAAGACGAGAGTGTGGAATCTAGCTTCTCCCTGAATGCCATCGAA 1554 
      ***** ** ** ******** ** *** ******* ******** ***** ********  
Rdm2  CCATGTGTGATTTGCCAGGGGCGGCCTAAAAATGGTTGCATTGTTCACGGCAAAACCGGA 1591 
Mdm2  CCATGTGTGATCTGCCAGGGGCGGCCTAAAAATGGCTGCATTGTTCACGGCAAGACTGGA 1614 
      *********** *********************** ***************** ** *** 
 
Rdm2  CACCTGATGTCATGTTTCACGTGTGCAAAGAAGCTAAAGAAGAGGAATAAGCCCTGCCCC 1651 
Mdm2  CACCTCATGTCATGTTTCACGTGTGCAAAGAAGCTAAAAAAAAGAAACAAGCCCTGCCCA 1674 
      ***** ******************************** ** ** ** ***********  
            Termination codon 
Rdm2  GTGTGCAGACAGCCGATCCAAATGATTGTGCTCACGTACTTCAACTAGACGGCGGGC--- 1708 
Mdm2  GTGTGCAGACAGCCAATCCAAATGATTGTGCTAACTTACTTCAACTAGCTGACCTGCTCA 1734 
      ************** ***************** ** ************  * *  **    
 
Rdm2  -AGACGCAGACCTTTACACTTCTAA-TGTATGACCCCCAAATTAGACAACATGGGTATTA 1766 
Mdm2  CAAAAATAGAATTTTATATTTCTAACTATATGACCCCCAAATTAGACAACATGGGTATTA 1794 
       * *   ***  **** * ****** * ******************************** 
     Reverse primer Rdm2(A) 
Rdm2  TTTTCATACATTAAAGCCGGAGCATTGTCTTAGTCTACATAAAGTTCATTTGTAATTTAT 1826 
Mdm2  TTTTTATACATTAAAGCCAGAAAACTGTCTTAGTCCACATAAAATTCACTTATAATTTAT 1854 
      **** ************* **  * ********** ******* **** ** ******** 
 
Rdm2  CCTCGAGAGTAAGAATAGTAACTGTTTTCTTCCTTTT-AGGAAAATTTCAGTTGATTATT 1885 
Mdm2  CCTGGAGAGTAAATATGGTGAATATTTTCTTCCTTTTTAGGGAAATTTCACTTGTTTATT 1914 
      *** ********  ** ** * * ************* *** ******** *** ***** 
 
Rdm2  TTATATTTGTGTTTTAACGTAATTTGCATTAGCTCTTTTCATTTTCCTTACGTTTTAAGT 1945 
Mdm2  TTATATTTGTGTTTTAA-GTAATTTGCATTGGCTGTTTATATTTTCCTTATATTTTAAAT 1973 
      ***************** ************ *** ***  **********  ****** * 
 
Rdm2  AATCTCCACTTGGAAGGACTTTTGAAAGTATACTTTATACAGTGAGAAGTCCTCTCCATC 2005 
Mdm2  AATCTCCGCTTGGAAGGACTTT-GGAAGTGTAT--------GTGAGAAGTCCTTTCCATC 2024 
      ******* ************** * **** **         ************ ****** 
 
Rdm2  TCTGTCTCTTGGAGATA----------ATGATAGGCTATCGAATTGTGCTTGATTTCCTT 2055 
Mdm2  TCCTGCAGATGATGGTGGACCTTCCTCATCAAGGGCTACAGAA--GTACTTGATTTCTGT 2082 
      **   *   **  * *           ** *  *****  ***  ** *********  * 
      AU-rich instability element 
Rdm2  TTTTTTCCTTGTTAAT------ATTTAATTTATTTAGTATCTTTCATGTAAAGAGTTAAA 2109 
Mdm2  TTTTTTTGTTAATAATAAGAACATTTAATTTATTTAGTGTCTTTCATGTAAAGAGTTAAA 2142 
      ******  **  ****      **************** ********************* 
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Rdm2  GACTATGTGAAGGATTGAGTGTATATTTAAGTTATTGAAATTCTGAACCTCCTTAGTTCT 2169 
Mdm2  GACTATGTGAAGGAT----TGTATATTTAAGTTATTGAAATTCTGAAACTGTAGTAATCT 2198 
      ***************    **************************** **       *** 
 
Rdm2  CTTAAGTGGGGGTTGTGGGCTGCAGAGAAGAGTCAGCCGGTAAAGGCGCCCACTGTGTAT 2229 
Mdm2  AAAATGTGTGAGTTGTGGGCTGCAGAGAAGACTCAGCCAGTAAAGGCACCTGCTGTGTAC 2258 
         * *** * ******************** ****** ******** **  *******  
 
Rdm2  GCCTAATGACACACATTTGATCCTTGCAACGCCCAGAAAGAGAGAACCAGTTCCACAAAG 2289 
Mdm2  ACCCACTGACACACATTTGATCCTTGGAACCCCCAGGAAGAGTGAACCAGTTCCACAAAG 2318 
       ** * ******************** *** ***** ***** ***************** 
 
Rdm2  TAGTTCTCGGATCTCCAAATGGATTCAT----------ATACACACTTTTTTTTT----- 2334 
Mdm2  TTGTTCCCTGATCTTCAAATGGATGCACGCATGCACGCACACACACGCGCGCGTGCGCAC 2378 
      * **** * ***** ********* **           * ******       *       
 
Rdm2  --------------------------------------------------TTTTTAAGGT 2344 
Mdm2  ACACACACACACACACACACACACACACACACACACACACACACACACAGTTTTAAAGGC 2438 
                                                        **** ****  
 
Rdm2  CTGAGTTGCATCTGGTGATACATAAGTGAAAACACACACCTTGTTTTCCAGC-------- 2396 
Mdm2  ATGAATTGCATCTGGTGGTATGTAAGTGAAAACACACGCCTTATTTTCCAGCATTTTCAG 2498 
       *** ************ **  *************** **** *********         
 
Rdm2  -TTTTTGTCATATGGGGTGTGGCACGAGTGTTGCAGTCTGTCCCAGGTTGAAAAAGTCTG 2455 
Mdm2  CTTTTTGTCATA-GGGGTGTGGCACAAGTGTTGCAGTTTGTCCCAGGTTGAAAA-GCCTG 2556 
       *********** ************ *********** **************** * *** 
 
Rdm2  TGGCCCTTCGAAGCACCTTCATGGCCC-GCTCCATGGTTCCTGATGGCTGTTGAAGTTTC 2514 
Mdm2  AGGCTGGTAGAAGCGCCTTTTTGCCTCAGCTCCGTGGTTCCTGGTGGTTGCCTATGTTTC 2616 
       ***   * ***** ****  ** * * ***** ********* *** **   * ***** 
 
Rdm2  AGGCCTGTACTTAGTCTAGGTT-AGAAACCAGTCCATTCAGAAAGACTAAATCAGAGCAT 2573 
Mdm2  AGGCCTGTACTTAGGCTAGGTTTAGAAACCAGCCCATTCAGAAAGACTGAATCAGAACAT 2676 
      ************** ******* ********* *************** ******* *** 
 
Rdm2  GGATGAAGTGGATCC----------------TCCAACCGTGTAGATGAGTCTCTTGATTC 2617 
Mdm2  GGATAAAGTGAACTCATTCTAAGATGACTCGTCTATCCATGTAGATTAATCTCCTGGTTC 2736 
      **** ***** *  *                ** * ** ******* * **** ** *** 
 
Rdm2  ATAATAAGAATCTTCCATTTTAATTGAAGGGTCATGCCTAAGTGTAGAAAACAAGTTCCC 2677 
Mdm2  ATAATAGGCCTCTTCC-CTTTGATTGAAGGGTCACGTCTAAGTATAGAAAACATAAAACT 2795 
      ****** *  ******  *** ************ * ****** *********     *  
 
Rdm2  TAACTGTATGGAGTAACCAAAGGATAGTTCTGTATTGAAGTTGACTTAAAGTATCAAAGA 2737 
Mdm2  GTAAGGTA--GAGGAAGCGAAGGATAGCTTTGTATTAATGTTGCGTTAAAGCTTCAGAGA 2853 
        *  ***  *** ** * ******** * ****** * ****  ******  *** *** 
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Rdm2  T-----------CACTCCCCACATGATTTAGCAGTTAAGTCGGAGGCAGCGCCTCAGCCT 2786 
Mdm2  CAAGAACAAGAACACTCCTCCCACGTGACAGCATTTGAATAGGAGGCGGTG-----GGTG 2908 
                  ****** * ** *    **** ** * * ****** * *     *    
 
Rdm2  GGGCATCCTAACTCTGGACTTTGATTCCCCATTTACAATGTAATACTGAGGTTATATCCT 2846 
Mdm2  CGGCAGCCTGG----GCAGCTTCAGTCCCGATTTACAATAAAGTACC----TTGT----- 2955 
       **** ***      * *  ** * **** *********  * ***     ** *      
 
Rdm2  AGTATTACTAGTTCTTAAATGTTTATTTAGGTGTGGTAGACATACATTATTTATTTGCAA 2906 
Mdm2  -GTGTTATTAGTTCTTAAATGTTTATTTAGAAATGGCATTGATG--TTATTTATTTGCAA 3012 
       ** *** **********************   *** *   **   ************** 
 
 
Polyadenylation signal      12 
Rdm2  ATAAATGGTTTATTGAATTGTTTC 2930 
Mdm2  ATAAATGGTTTATTG--------- 3027 
      ***************          
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Mdm2 GTACCCGC----------TCCGTGGGCGGCGGAGAGTCCCGATCATTCCC--TCTTTTCC 48
Rdm2 GTACCCGCCAGGAGCGACGCGACGTGCGGGGTTGGGCGGTGGCGAGTTCTGATCATTCCC 60
HDM2 GTACTGGCCCGG----------CAGCGAGCGGTCACTTTTGGGTCTGGGCT-CTGACGGT 49
     **** ***                    * *         *           *              
   
      MZF-1 RE
Mdm2 GCGCCCTCCGGGGCCTACTCGTAACCCGGGCCGGCTCGTGGGGTC-GCGGGGCACGAGGC 107
Rdm2 GAGTCCTCTGGGGCCCACTCGCAGCCCGAGACGGCTCGCGGGGTC-GCGGGGC------- 112
HDM2 GTCCCCTCTATCGCTGGTTCCCAGCCTCTGCCCGTTCGCAGCCTTTGTGCGGTTCGTGGC 109
     *   ****    **    **  * **   * * * ***  *  *  * * **        
  GGGGC repeats  E-box
Mdm2 TGGGCGACCGTTTGCCCGCGC-TGGGCCCTGATGTCATTCTGCGGCCGGGGGTGTGCGTG 166
Rdm2 -----GACGGTTTGTTGGCGC-CGGGCCATGATGCCCTTATTCATCAGGGTG-------- 158
HDM2 TGGGGGCTCGGGGCGCGGGGCGCGGGGCATGG-GGCACGTGGCTTTGCGGAGGTTTTGTT 168
          *   *       * **  *** * **  * *      *     ** *        
Mdm2 TGGGTGGGAGTGGGGGGTGG--GGTGGGAGATGGCGCGG---TTAGCACGGCGCATGCGC 221
Rdm2 -AGGTGGG---GGGGTCTGG--GTTAACACAGCGCACGC---GCGGAA--GAGGATG-AC 206
HDM2 GGACTGGGGCTAGGCAGTCGCCGCCAGGGAGGAGGGCGGGATTTCGGACGGCTCTCGCGG 228
         ****    **   * *  *          *  **       * *  *     *   
 MZF-1 RE     MZF-1 RE
Mdm2 GGGAGGGGACGGAGGGAGGGGGAGGAGGGAAGAGCGGGGGTCTCCCA-GCAGGCCCCGCG 280
Rdm2 GGG-GGTAATGGAGGGAGGGG-AGAGGAGAAGAGCCGGGGTCTCCCG-GCAGGCCCCGCG 263
HDM2 CGGTGGGGGTGGGGGTGGTTC--GGAGGTCTCCGCGGGAGTTCAGGGTAAAGGTCACGGG 286
      ** **    ** **  *     *  *      ** ** **         *** * ** *
  Ets RE
Mdm2 CGCGGGGGGCCCGCTCCGGGGTCGCGCTGGGCTCGTTGCTGGGGTCCAGGAGGTGACAGG 340
Rdm2 CCCGGGGG--CGGCTCCGGGGTCGCGCTGGGCTCACTGCAGGGGTCGGGGAGGTAACAGG 321
HDM2 GGCCGGGG----GCTGCGGGGCCGCTTCGG---CGCGG--GAGGTCCGGATGATCGCAGG 337
       * ****    *** ***** ***   **   *   *  * ****  *  * *  ****
  Ets RE
Mdm2 TGCCTGGTCCCGGACTCGCCGGGATGCGGCTTCCGGGACGGGTGGGACTGGGCTGG---- 396
Rdm2 TGCCTGGT---------GGTGGGACGTGGCTTCCGGGACGGGTGGGACTGGGCTGT---- 368
HDM2 TGCCTGTCGGGTCACTAGTGTGAACGCTGCGCGTAGTCTGGGCGGGATTGGGCCGGTTCA 397
     ******           *   * * *  **     *   *** **** ***** *     
    AP-1 RE   Ets RE      p53 RE
Mdm2 ---GCCGAG GGCT GGCGTC 453TTGACTCAG CTCTTCCTGTGG GGTCAAGTTGGGACACGTCC
Rdm2 ---GCCTAG GGCT AGCGTT 425TTGACTCAG CTTTTCCTGTGG GGTCAAGTTAGGACACGTTC
HDM2 GTGGGCAGG AGCT CGAAAC 457TTGACTCAG CTTTTCCTCTTG GGTCAAGTTCAGACACGTTC
        * *  ************ ***** * * ************  ******* * *    
12
  p53 RE
Mdm2 GGCTGTCGGAGG CCAGCTGGGGTTATTTAAACGCTGCCCC 513AGCTAAGTCCTGACATGTCT
Rdm2 GGCTGTTGGAGG CCAGCTGAGGCTATTTAAACCCTGCTC- 484AGCTAAGTCCTGACATGTCT
HDM2 TGCAGTAAAAGG CCAGCTGGGGCTATTTAAACCATGCATT 517AGTTAAGTCCTGACTTGTCT
      ** **   ***** *********** ************ ** *********  ***   
Mdm2 GTTTCCGCAG-------------------------------------------------- 523
Rdm2 GTTTCCGCAG-------------------------------------------------- 494
HDM2 --TTCC-CAGCTGTGTTCAGTGGCGATTGGAGGGTAGACCTGTGGGCACGGACGCACGCC 574
       **** ***                                                  
Mdm2 ------------------------------------------------------------
Rdm2 ------------------------------------------------------------
HDM2 ACTTTTTCTCTGCTGATCCAGGTAAGCACCGACTTGCTTGTAGCTTTAGTTTTAACTGTT 634
                                                                        
   
Mdm2 ------------------------------------------------------------
Rdm2 ------------------------------------------------------------
HDM2 GTTTATGTTCTTTATATATGATGTATTTTCCACAGATGTTTCATGATTTCCAGTTTTCAT 694
                                                                        
   
Mdm2 ----------------------
Rdm2 ----------------------
HDM2 CGTGTCTTTTTTTTCCTTGTAG 716
